[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 640
1. Stoica LE, Georgescu CV, Pătraşcu V, Radu CC, Tolea I, Mogoantă L: Basal cell carcinomas - clinical-evolutional and histopahotologic aspects. Curr Health Sci J; 2009 Oct;35(4):228-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas - clinical-evolutional and histopahotologic aspects.
  • Basal cell carcinoma (BCC) is the most frequent cutaneous tumour.
  • Having as aim the identification of the clinical-evolutional and histopathologic aspects of the basal cell carcinomas, we have undertaken a retrospective study for a period of 5 years, from 1st January 2004 to 31st December 2008, on 706 patients interned in the Dermatology Clinic of Craiova, whom indicated 738 tumours.
  • A clinical data was drawn for the patients, containing the identification data, environment, profession, cancer localisation and history of the disease, clinical and histopathologic diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24778822.001).
  • [ISSN] 2067-0656
  • [Journal-full-title] Current health sciences journal
  • [ISO-abbreviation] Curr Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3945250
  • [Keywords] NOTNLM ; basal cell carcinoma / evolution / histopathology
  •  go-up   go-down


2. Terstappen K, Larkö O, Wennberg AM: Pigmented basal cell carcinoma--comparing the diagnostic methods of SIAscopy and dermoscopy. Acta Derm Venereol; 2007;87(3):238-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented basal cell carcinoma--comparing the diagnostic methods of SIAscopy and dermoscopy.
  • Pigmented basal cell carcinomas can be difficult to distinguish clinically from melanoma.
  • Dermoscopy has proven to be useful in the differential diagnosis of the two tumour types.
  • The aim of this study was to evaluate whether SIAscopy can be useful in diagnosing pigmented basal cell carcinomas.
  • Twenty-one pigmented basal cell carcinomas were analysed, comparing dermoscopic and SIAscopic findings.
  • The results, in this limited setting, show that SIAscopy has no advantages over dermoscopy when diagnosing pigmented basal cell carcinomas.
  • On the contrary, pigmented basal cell carcinomas show, in SIAscopy, similar features to those previously reported for melanoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy. Skin Neoplasms / pathology. Spectrophotometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533490.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Melanins; 9007-34-5 / Collagen
  •  go-up   go-down


3. Fernandez-Flores A: Advanced differentiation in trichoepithelioma and basal cell carcinoma investigated by immunohistochemistry against neurofilaments. Folia Histochem Cytobiol; 2009;47(1):61-4
MedlinePlus Health Information. consumer health - Hair Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced differentiation in trichoepithelioma and basal cell carcinoma investigated by immunohistochemistry against neurofilaments.
  • Basal cell carcinoma (BCC) and trichoepithelioma (TE) are sometimes diagnostic challenges for the pathologist in terms of their differential diagnosis.
  • Although literature is quite rich in information about histologic and immunohistochemical clues to distinguish the differences between both, no single finding must be completely reliable.
  • Moreover, some consider that TE is a better differentiated follicular tumour, while BCC represents a less developed stage in differentiation.
  • Since this plexus is a late sign of differentiation and since both types of neoplasias share it, we conclude that TE and BCC are both terminally differentiated neoplasms.
  • The ability of BCC to infiltrate would have more to do with the acquisition by the tumour of such a property, rather than with a stage of indifferentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419939.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Madras J, Lapointe H: Keratocystic odontogenic tumour: reclassification of the odontogenic keratocyst from cyst to tumour. J Can Dent Assoc; 2008 Mar;74(2):165-165h
Hazardous Substances Data Bank. CHLOROFORM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratocystic odontogenic tumour: reclassification of the odontogenic keratocyst from cyst to tumour.
  • The purpose of this paper is to review the features and behaviour of the odontogenic keratocyst (OKC), now officially known as the keratocystic odontogenic tumour (KCOT); to analyze a series of histologically confirmed KCOT cases; and to review and discuss the redesignation of KCOT and the implications for treatment.
  • Abnormal function of PTCH, a tumour suppressor gene, is noted to be involved in both nevoid basal cell carcinoma syndrome and sporadic KCOTs.
  • A review of the literature was conducted and results were tabulated to determine whether treatment modality is related to recurrence rate.
  • WHO"s reclassification of the OKC as the KCOT based on behaviour, histology and genetics underscores the aggressive nature of the lesion and should motivate clinicians to manage the disease in a correspondingly aggressive manner.
  • [MeSH-major] Jaw Diseases / classification. Jaw Neoplasms / classification. Odontogenic Cysts / classification. Odontogenic Tumors / classification
  • [MeSH-minor] Acetic Acid / therapeutic use. Age Distribution. Aged. Aged, 80 and over. Chloroform / therapeutic use. Ethanol / therapeutic use. Humans. International Classification of Diseases. Keratins. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetics Home Reference. consumer health - Gorlin syndrome.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Tex Dent J. 2008 May;125(5):446-54 [18561800.001]
  • (PMID = 18353202.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Carnoy's solution; 3K9958V90M / Ethanol; 68238-35-7 / Keratins; 7V31YC746X / Chloroform; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


5. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


6. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, Robbins PA: Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med; 2006 Jul;3(7):e290
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology.
  • BACKGROUND: The von Hippel-Lindau tumour suppressor protein-hypoxia-inducible factor (VHL-HIF) pathway has attracted widespread medical interest as a transcriptional system controlling cellular responses to hypoxia, yet insights into its role in systemic human physiology remain limited.
  • Chuvash polycythaemia has recently been defined as a new form of VHL-associated disease, distinct from the classical VHL-associated inherited cancer syndrome, in which germline homozygosity for a hypomorphic VHL allele causes a generalised abnormality in VHL-HIF signalling.
  • Basal ventilation and pulmonary vascular tone were elevated, and ventilatory, pulmonary vasoconstrictive, and heart rate responses to acute hypoxia were greatly increased.
  • [MeSH-major] Adaptation, Physiological / genetics. Altitude. Cardiovascular Physiological Phenomena. Hypoxia / physiopathology. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Polycythemia / genetics. Respiratory Physiological Phenomena. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2000 Mar 15;35(4):980-7 [10732898.001]
  • [Cites] J Appl Physiol. 1969 Jun;26(6):757-9 [5786406.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H2013-6 [11009492.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L202-8 [11404263.001]
  • [Cites] Chest. 2001 Sep;120(3):801-8 [11555513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):821-6 [11792862.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):614-21 [12415268.001]
  • [Cites] J Appl Physiol (1985). 2003 Apr;94(4):1543-51 [12482766.001]
  • [Cites] Am J Respir Crit Care Med. 2003 May 1;167(9):1193-9 [12714342.001]
  • [Cites] J Clin Invest. 2003 May;111(10):1519-27 [12750401.001]
  • [Cites] J Appl Physiol (1985). 1992 Jul;73(1):101-7 [1506356.001]
  • [Cites] Cardiovasc Res. 1997 May;34(2):384-92 [9205553.001]
  • [Cites] Respir Physiol. 1969 Oct;7(3):369-82 [4898680.001]
  • [Cites] J Clin Invest. 1972 Jun;51(6):1469-75 [4336940.001]
  • [Cites] J Appl Physiol. 1975 May;38(5):846-50 [1126894.001]
  • [Cites] J Appl Physiol Respir Environ Exerc Physiol. 1982 May;52(5):1353-7 [6807948.001]
  • [Cites] J Appl Physiol Respir Environ Exerc Physiol. 1983 Oct;55(4):1167-72 [6629949.001]
  • [Cites] Circulation. 1984 Oct;70(4):657-62 [6478568.001]
  • [Cites] Clin Physiol Biochem. 1984;2(4):176-83 [6488695.001]
  • [Cites] J Appl Physiol (1985). 1987 Aug;63(2):521-30 [3654410.001]
  • [Cites] Respir Med. 1990 Jul;84(4):335-7 [2236761.001]
  • [Cites] J Neurochem. 1992 Apr;58(4):1538-46 [1347783.001]
  • [Cites] Eur Respir J. 1992 May;5(5):525-30 [1612153.001]
  • [Cites] Am J Physiol. 1997 Sep;273(3 Pt 2):H1126-34 [9321798.001]
  • [Cites] J Clin Invest. 1999 Mar;103(5):691-6 [10074486.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] J Appl Physiol (1985). 1999 Jun;86(6):1897-904 [10368354.001]
  • [Cites] J Appl Physiol (1985). 2005 Mar;98(3):1125-39 [15542574.001]
  • [Cites] J Physiol. 2005 Oct 15;568(Pt 2):559-71 [16051624.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1097-9 [12702509.001]
  • [Cites] Blood. 2004 May 15;103(10):3924-32 [14726398.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 [15122348.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):20-30 [15137054.001]
  • [Cites] Ann Intern Med. 2004 Aug 3;141(3):169-77 [15289213.001]
  • [Cites] Physiology (Bethesda). 2004 Aug;19:176-82 [15304631.001]
  • [Cites] N Engl J Med. 2004 Oct 14;351(16):1655-65 [15483284.001]
  • [Cites] Chest. 2004 Oct;126(4):1313-7 [15486398.001]
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):423-7 [10878807.001]
  • (PMID = 16768548.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / ; United Kingdom / Medical Research Council / / MRC/ G116/127
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 142M471B3J / Carbon Dioxide; E1UOL152H7 / Iron; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase; EC 6.3.2.- / VHL protein, human; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC1479389
  •  go-up   go-down


7. Hallock GG, Bulatao IS: Basal cell carcinoma masquerading as a hallux valgus. Can J Plast Surg; 2007;15(1):47-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma masquerading as a hallux valgus.
  • Ultimately, a shave biopsy revealed that the lesion was a basal cell carcinoma.
  • Wide local excision and another skin graft resulted in tumour eradication and, finally, healing.
  • Basal cell carcinoma associated with a hallux valgus has not been previously reported, and this reinforces the concept that malignant degeneration as the cause of any chronic ulceration should not be overlooked.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2004 Apr 1;113(4):1297-9 [15083055.001]
  • [Cites] Plast Reconstr Surg. 2004 Mar;113(3):1101-3 [15108936.001]
  • [Cites] Plast Reconstr Surg. 1995 Jan;95(1):199-200 [7809242.001]
  • [Cites] Ann Plast Surg. 1990 Feb;24(2):186-8 [2316978.001]
  • [Cites] Clin Podiatr Med Surg. 1993 Jan;10(1):79-95 [8431842.001]
  • [Cites] J Am Podiatry Assoc. 1978 Oct;68(10):693-5 [690378.001]
  • (PMID = 19554132.001).
  • [ISSN] 1195-2199
  • [Journal-full-title] The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique
  • [ISO-abbreviation] Can J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2686046
  • [Keywords] NOTNLM ; Basal cell carcinoma / Hallux valgus / Skin cancer
  •  go-up   go-down


8. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Boran C, Parlak AH, Erkol H: Collision tumour of trichofolliculoma and basal cell carcinoma. Australas J Dermatol; 2007 May;48(2):127-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of trichofolliculoma and basal cell carcinoma.
  • Histopathological examination revealed that the nodule was composed of trichofolliculoma and basal cell carcinoma.
  • There was no transitional zone between the two neoplasms.
  • The diagnosis was made as a collision tumour of trichofolliculoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Hair Follicle / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Trichofolliculoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535204.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Apaydin R, Gürbüz Y, Bayramgürler D, Bilen N: Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study. Amyloid; 2005 Mar;12(1):41-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
  • We investigated the expression of CKs immunohistochemically in basal cell carcinomas (BCCs), epidermis overlying tumour, and skin tumor-associated amyloidosis (STA).
  • In BCCs without STA, CK1-8, CK14 and CK17 antibodies were expressed by tumour tissue in all biopsy specimens.
  • In the BCCs with STA, tumour tissue was immunoreactive always with CK1-8 and CK17 antibodies, and commonly immunoreactive with anti-CK 14 antibody.
  • In the epidermis overlying tumour tissue, there was positive immunoreactivity with anti-CK 1-8, CK 5/6/18, CK 10 and CK 14 antibodies in all biopsy specimens.
  • Weak positivity and a few number of CKs were shown in STA when compared with those of BCC and epidermis overlying tumour tissue expressing the more variable CKs.
  • [MeSH-major] Amyloidosis / metabolism. Carcinoma, Basal Cell / metabolism. Epidermis / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076610.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


12. Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M: [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]. Pathologe; 2008 Nov;29 Suppl 2:347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
  • [Transliterated title] Expression des "activated leukocyte cell adhesion molecule" im Mammakarzinom. Prädiktivität für das Ansprechen auf eine taxanfreie Chemotherapie.
  • AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression.
  • RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells.
  • [MeSH-major] Antigens, CD / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / genetics. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Cell Adhesion Molecules, Neuronal / genetics. Fetal Proteins / genetics. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Taxoids / administration & dosage
  • [MeSH-minor] Blotting, Western. Breast / pathology. Chemotherapy, Adjuvant. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Receptors, Estrogen / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810438.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Taxoids
  •  go-up   go-down


13. Blasdale C, Charlton FG, Weatherhead SC, Ormond P, Lawrence CM: Effect of tissue shrinkage on histological tumour-free margin after excision of basal cell carcinoma. Br J Dermatol; 2010 Mar;162(3):607-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tissue shrinkage on histological tumour-free margin after excision of basal cell carcinoma.
  • BACKGROUND: Histology reports of skin tumour excisions frequently describe a histological margin significantly less than the planned surgical excision margin.
  • OBJECTIVES: A novel method of marking visible tumour margin was devised.
  • This allowed us to evaluate the accuracy of tumour detection and to compare tissue contraction of the clinically normal perilesional skin with that of tumour tissue following excision and fixation.
  • METHODS: Forty-four well-defined basal cell carcinomas were excised from 42 patients.
  • The visible tumour edge was marked by scoring with a blade around its circumference prior to excision.
  • This allowed comparison of visible and true histological tumour margin.
  • The excision margin was carefully measured from the scored line and the tumour excised.
  • After tissue fixation and processing the histological dimensions of tumour and perilesional margin skin were compared with the pre-excision measurements.
  • RESULTS: The tumour edge was accurately identified to within 1 mm in 67% of margins and was underestimated in only 4%.
  • Skin containing tumour contracted by a mean of 11% but adjacent tumour-free skin in the same plane contracted by a mean of 19%.
  • There was no significant effect of age and site on difference in percentage shrinkage between tumour and margin.
  • CONCLUSIONS: We underestimated tumour extent at only 4% of margins.
  • Our novel technique allowed us to demonstrate that this shrinkage is not uniform across the specimen, but is disproportionately high in the tumour-free margin.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Risk Assessment. Sensitivity and Specificity. Statistics as Topic. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906070.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Kopriva I, Persin A: Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation. Med Image Anal; 2009 Jun;13(3):507-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation.
  • Such situation arises when low-dimensional low-intensity multi-spectral image of the tumour in the early stage of development is represented by the SLMM, wherein tumour is spectrally similar to the surrounding tissue.
  • The original contribution of this paper is in proposing an algorithm for unsupervised decomposition of low-dimensional multi-spectral image for high-contrast tumour visualisation.
  • We demonstrate good performance of the method on both computational model and experimental low-intensity red-green-blue fluorescent image of the surface tumour (basal cell carcinoma).
  • [MeSH-major] Algorithms. Artificial Intelligence. Image Interpretation, Computer-Assisted / methods. Microscopy, Fluorescence / methods. Pattern Recognition, Automated / methods. Skin Neoplasms / pathology. Spectrometry, Fluorescence / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282233.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Kanellou P, Zaravinos A, Zioga M, Spandidos DA: Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. Br J Dermatol; 2009 Jun;160(6):1215-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a locally aggressive slowly growing tumour that rarely metastasizes and is mostly seen in older members of the population.
  • OBJECTIVES: To determine the involvement of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in BCC.
  • Moreover, we studied the mRNA expression levels of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in the BCC samples and compared them with mRNA levels in the corresponding normal tissue.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor / physiology. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Mutational Analysis / methods. Female. Genes, p16. Genes, p53. Heterozygote. Humans. Loss of Heterozygosity. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Polymerase Chain Reaction / methods. RNA, Messenger / metabolism. Statistics as Topic. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298278.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Lear JT, Hoban P, Strange RC, Fryer AA: Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes. Clin Exp Dermatol; 2005 Jan;30(1):49-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes.
  • The molecular factors and events that characterize susceptibility and outcome in cutaneous basal cell carcinoma (BCC) have been the focus of much research interest.
  • While the search for susceptibility genes has generally resulted in the identification of low penetrance allelic variants, studies on modifier genes influencing outcome variables such as tumour number, age of onset and tumour subtype have identified factors with higher potential impact.
  • Here we will briefly describe some recent work on the genetic basis of the immune response to UVR, the effect of UVR on the generation of reactive oxygen species and their detoxification, and the role of onco- and tumour suppressor genes.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA Damage. Genes, Tumor Suppressor. Neoplasms, Radiation-Induced / genetics. Skin Neoplasms / genetics. Sunlight / adverse effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Female. Genetic Predisposition to Disease. Humans. Male. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663504.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


17. Garcia L, Nagore E, Llombart B, Sanmartin O, Botella-Estrada R, Requena C, Jorda E, Guillen C: Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):926-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nasolabial fold: an apparently 'benign' tumour that often needs complex surgery.
  • BACKGROUND: Location of the tumour is a well-known prognostic factor for recurrence of basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922939.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Garcia-Carbonero R, Agullo-Ortuño MT, Lopez-Rios F, Diaz-Garcia CV, Cortijo A, Cortes-Funes H, Paz-Ares L: Evaluation on the IGF-IR Inhibitor CP-751,871, alone and in combination with paclitaxel in lung and colon cell lines. J Clin Oncol; 2009 May 20;27(15_suppl):e22125

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation on the IGF-IR Inhibitor CP-751,871, alone and in combination with paclitaxel in lung and colon cell lines.
  • The aim of this study was to assess the direct anti-tumour effects of CP-751,871, alone and in combination with paclitaxel in lung and colon cancer cell lines.
  • METHODS: Four lung and four colon cancer cell line where treated with the IGF-IR inhibitor CP-751,871 and/or Paclitaxel in simultaneous or sequential treatments.
  • Response to treatments was evaluated by WST-1 cell survival assays.
  • Flow cytometric analysis was used to estimate the effect on the cell cycle and apoptosis.
  • RESULTS: No correlation between basal IGF-IR mRNA expression and CP-751,871 response was observed in cell lines tested.
  • Flow cytometric analysis demonstrated that CP-751,871 enhanced cell cycle arrest at the G1/G0 checkpoint with minimal effects on apoptosis.
  • Combined simultaneous and, more strongly, sequential treatment with CP- 751,871 and Paclitaxel showed improved response in cell growth inhibition on HCC78, H1299, Colo205 and HT29 cell lines, and was statistically superior to Paclitaxel alone (p< 0.001) and CP-751,871 alone (p< 0.001).
  • In H460, LS180 and DLD-1 cell lines, concomitant, but no sequential treatment resulted in antagonistic interactions.
  • CONCLUSIONS: CP-751,871 showed a modest anti-tumour activity, predominantly cytostatic, against lung and colon cancer cell lines, that is not related to the mRNA expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963563.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Papanikolaou S, Bravou V, Gyftopoulos K, Nakas D, Repanti M, Papadaki H: ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology; 2010 May;56(6):799-809
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion.
  • AIMS: Epithelial-mesenchymal transition (EMT) has been known to play a significant role in tumour progression.
  • The aim was to study ILK expression and its relevance to EMT markers in human basal cell carcinoma (BCC).
  • ILK overexpression was observed in 100% of cases and strongly correlated with tumour invasion and infiltrative BCC.
  • Aberrant expression of E-cadherin, nuclear beta-catenin and alpha-SMA correlated with BCC tumour invasion.
  • CONCLUSIONS: ILK overexpression in BCC is implicated in tumour progression probably through the induction of an EMT-related molecular profile.
  • Nuclear localization of E-cadherin in BCC is also associated with aggressive tumour features.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Epithelial Cells / metabolism. Mesenchymal Stromal Cells / metabolism. Protein-Serine-Threonine Kinases / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cadherins / metabolism. Humans. Immunohistochemistry. Neoplasm Invasiveness. Transcription Factors / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546345.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Transcription Factors; 0 / beta Catenin; 0 / snail family transcription factors; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


20. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • All patients underwent excision of the tumour with maximum margins of 2 mm.
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG: Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol; 2006 Dec;155(6):1154-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
  • BACKGROUND: Extensive exposure to ultraviolet radiation is associated with genetic alterations in basal cell carcinomas (BCCs), which represent some 75% of skin cancers.
  • OBJECTIVES: As recent data suggested the fragile histidine triad (FHIT) gene product to participate in DNA damage responses we wished to address whether functional deletion of this tumour suppressor participates in the development of BCC.
  • CONCLUSIONS: We have identified epigenetic silencing of the FHIT tumour suppressor gene as a frequent inactivation mechanism which is likely to contribute to functional deficiencies in DNA damage response of BCCs.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Carcinoma, Basal Cell / genetics. Gene Silencing. Genes, Tumor Suppressor. Neoplasm Proteins / genetics. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107382.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


22. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA, Blanpain C: Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol; 2010 Mar;12(3):299-305

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the cell lineage at the origin of basal cell carcinoma.
  • For most types of cancers, the cell at the origin of tumour initiation is still unknown.
  • Here, we used mouse genetics to identify cells at the origin of basal cell carcinoma (BCC), which is one of the most frequently occurring types of cancer in humans, and can result from the activation of the Hedgehog signalling pathway.
  • Our studies uncover the cells at the origin of BCC in mice and demonstrate that expression of differentiation markers in tumour cells is not necessarily predictive of the cancer initiating cells.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Lineage. Epidermis / pathology
  • [MeSH-minor] Animals. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Cadherins / metabolism. Cell Count. Cell Differentiation. Clone Cells / metabolism. Clone Cells / pathology. Ear, External / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Genes, Reporter / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Hedgehog Proteins / genetics. Integrases / genetics. Integrin beta4 / metabolism. Keratin-10 / metabolism. Keratin-14 / genetics. Keratin-15 / genetics. Keratin-15 / metabolism. Keratin-19 / genetics. Kruppel-Like Transcription Factors / metabolism. Luminescent Proteins / genetics. Luminescent Proteins / metabolism. Mice. Mice, Inbred Strains. Mice, Transgenic. Models, Biological. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Proteins / genetics. Proteins / metabolism. RNA, Untranslated. Receptors, Cell Surface / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Skin / metabolism. Skin / pathology. Tail / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cell Stem Cell. 2010 Apr 2;6(4):292-4 [20362530.001]
  • (PMID = 20154679.001).
  • [ISSN] 1476-4679
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cadherins; 0 / Gt(ROSA)26Sor non-coding RNA, mouse; 0 / Hedgehog Proteins; 0 / Integrin beta4; 0 / Keratin-14; 0 / Keratin-15; 0 / Keratin-19; 0 / Krt1-10 protein, mouse; 0 / Krt1-14 protein, mouse; 0 / Krt1-15 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / Luminescent Proteins; 0 / Proteins; 0 / RNA, Untranslated; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Shh protein, mouse; 0 / Smo protein, mouse; 0 / patched receptors; 0 / yellow fluorescent protein, Bacteria; 147785-83-9 / Keratin-10; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


23. Porse BT, Petersen OW, Helin K: [Basic stem cell biology and cancer]. Ugeskr Laeger; 2010 Sep 20;172(38):2600-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basic stem cell biology and cancer].
  • [Transliterated title] Basal stamcellebiologi og cancer.
  • The finding that tumours, like normal tissues, are endowed with varying degrees of cellular heterogeneity has far-reaching consequences for our understanding of cancer.
  • The cancer stem cell and clonal evolution models have both been proposed to explain tumour-associated cellular heterogeneity.
  • Finally, we discuss the close association between basic stem cell biology and cancer, focusing on the role of self-renewal.
  • [MeSH-major] Neoplasms / pathology. Neoplastic Stem Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20920403.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Asplund A, Gry Björklund M, Sundquist C, Strömberg S, Edlund K, Ostman A, Nilsson P, Pontén F, Lundeberg J: Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br J Dermatol; 2008 Mar;158(3):527-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma.
  • BACKGROUND: Basal cell carcinomas (BCCs) are prevalent tumours with uniform histology that develop without any known precursor lesion.
  • METHODS: We used laser-assisted microdissection to isolate and collect cell populations defined under the microscope.
  • Peripheral cells from nests of BCC were selected to represent tumour cells, and normal keratinocytes from epidermis basal layer were used as control.
  • Furthermore, tumour cells appear to have an increased sensitivity to oxygen radicals and dysregulated genes involved in antigen presentation.
  • We found that expression patterns were significantly altered in BCC cells compared with basal keratinocytes and that the Wnt signalling pathway was upregulated in tumour cells.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Keratinocytes / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241271.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


25. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H: Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol; 2007 Dec;157 Suppl 2:47-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and aetiology of basal cell carcinoma.
  • Basal cell carcinoma (BCC) is a malignant epithelial neoplasm of the skin preferentially affecting male caucasians and is rarely observed in patients with more intense skin pigmentation.
  • Epidemiological data indicate that the overall incidence is increasing worldwide significantly by about 3-10% per annum.(1-3) Based on the increasing incidence of this usually not life-threatening tumour BCC appears to develop into a growing public health problem.
  • This review elucidates the risk factors for the development and for the progression of BCC leading to an improved understanding of this tumour.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Disease Progression. Humans. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067632.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


26. Sun ZJ, Liu B, Zhao YF: Radiopacity in syndrome keratocystic odontogenic tumour. Dentomaxillofac Radiol; 2008 Mar;37(3):175-8
Hazardous Substances Data Bank. HYDROXYAPATITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiopacity in syndrome keratocystic odontogenic tumour.
  • A case of dystrophic calcification in the cavity of the cyst of a patient with a syndromatic keratocystic odontogenic tumour was detected on panoramic radiograph and CT.
  • [MeSH-major] Basal Cell Nevus Syndrome / complications. Mandibular Neoplasms / radiography. Maxillary Neoplasms / radiography. Odontogenic Cyst, Calcifying / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316511.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 91D9GV0Z28 / Durapatite
  •  go-up   go-down


27. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene; 2006 Apr 6;25(15):2273-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of breast cell lines identifies potential new basal markers.
  • A better molecular characterization of breast cell lines (BCL) may help discover new markers to apply to tumour samples.
  • We performed gene and protein expression profiling of 31 BCL using whole-genome DNA microarrays and immunohistochemistry (IHC) on 'cell microarrays' (CMA), respectively.
  • Global hierarchical clustering discriminated two groups of BCL: group I corresponded to luminal cell lines, group II to basal and mesenchymal cell lines.
  • Correlations with centroids calculated from a published 'intrinsic 500-gene set' assigned 15 cell lines as luminal, eight as basal and four as mesenchymal.
  • A set of 1.233 genes was differentially expressed between basal and luminal samples.
  • Mesenchymal and basal subtypes were rather similar and discriminated by only 227 genes.
  • The expression of 10 proteins (CAV1, CD44, EGFR, MET, ETS1, GATA3, luminal cytokeratin CK19, basal cytokeratin CK5/6, CD10, and ERM protein moesin) encoded by luminal vs basal discriminator genes confirmed the subtype classification and the validity of the identified markers.
  • Our BCL basal/luminal signature correctly re-classified the published series of tumour samples that originally served to identify the molecular subtypes, suggesting that the identified markers should be useful for tumour classification and might represent promising targets for disease management.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Basal Cell / metabolism. Gene Expression Profiling


28. Simeonov R, Simeonova G: Nucleomorphometric analysis of feline basal cell carcinomas. Res Vet Sci; 2008 Jun;84(3):440-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleomorphometric analysis of feline basal cell carcinomas.
  • Twenty-four feline spontaneous basal cell carcinomas (BCCs) were analyzed by computerized nuclear morphometry.
  • The results indicate that nuclear morphometry is able to predict recurrent tumour growth and helps to differentiate histological subtypes of BCCs in cats.
  • [MeSH-major] Carcinoma, Basal Cell / veterinary. Cat Diseases / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706734.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Asplund A, Sivertsson A, Bäckvall H, Ahmadian A, Lundeberg J, Ponten F: Genetic mosaicism in basal cell carcinoma. Exp Dermatol; 2005 Aug;14(8):593-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic mosaicism in basal cell carcinoma.
  • Human basal cell cancer (BCC) shows unique growth characteristics, including a virtual inability to metastasize, absence of a precursor stage and lack of tumour progression.
  • The clonal nature of BCC has long been a subject for debate because of the tumour growth pattern.
  • Four parts of each individual tumour plus isolated samples of stroma were analysed following laser-assisted microdissection.
  • In 12/13 tumours, the epithelial component of the tumour showed a monoclonal pattern suggesting a unicellular origin.
  • Surprisingly, one tumour showed evidence of being composed of at least two non-related monoclonal clones.
  • This finding was supported by the analysis of the ptch and p53 gene.
  • Clonality analysis of tumour stroma showed both mono- and polyclonal patterns.
  • The study results show that what appears to be one tumour may occasionally constitute two or more independent tumours intermingled or adjacent to each other, possibly reflecting a local predisposition to malignant transformation.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic. Mosaicism. Neoplasms, Glandular and Epithelial / genetics. Receptors, Androgen / genetics
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, X. DNA / metabolism. Disease Progression. Dosage Compensation, Genetic. Epidermis / metabolism. Epithelium / metabolism. Female. Heterozygote. Humans. Lasers. Loss of Heterozygosity. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026581.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 109400
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


30. Khandwala MA, Lalchan SA, Chang BY, Habib M, Chakrabarty A, Cassells-Brown A: Outcome of periocular basal cell carcinoma managed by overnight paraffin section. Orbit; 2005 Dec;24(4):243-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of periocular basal cell carcinoma managed by overnight paraffin section.
  • BACKGROUND: Surgical excision of periocular skin cancer allows for optimum control in terms of tumour recurrence.
  • All patients had surgical excision of the tumour with a 3-mm margin.
  • If tumour was still present, a further 3-mm margin was excised at the appropriate edge(s) before reconstruction took place.
  • RESULTS: This study yielded 93 basal cell carcinomas (BCCs) of which 86 were of primary origin and 7 were recurrent tumours.
  • The tumour characteristics were as follows: 88% nodular BCCs, 82% had a maximum surface measurement less than or equal to 10 mm, 39.8% were inner canthal and 49.5% were localised to the lower lid.
  • In the 30 (35.4%) cases that required further excision based on the initial histological reports, tumour was seen in only four (11.4%) cases.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Paraffin Embedding / methods
  • [MeSH-minor] Aged. Female. Humans. Male. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354633.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Lin YW, Yan MD, Shih YL, Hsieh CB: The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. Eur J Cancer; 2009 Jul;45(11):2041-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma.
  • Our previous data showed that the smallest common deleted region was between D16S415 and D16S419, encompassed approximately by a 0.75cM region on 16q12.2, suggesting that the putative tumour suppressor genes (TSGs) at this locus might be involved in the development of HCC.
  • Downregulation of RPGRIP1L was found in 91% (10/11) HCC cell lines and in 35% (14/40) HCCs, respectively.
  • To investigate the role of RPGRIP1L in HCCs, we used the overexpression of RPGRIP1L in four HCC cell lines (HepG2, Huh6, Huh7 and Hep3B).
  • Overexpression of RPGRIP1L suppressed colony formation of tumour cells.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Carcinoma, Hepatocellular / genetics. Genes, Tumor Suppressor. Liver Neoplasms / genetics
  • [MeSH-minor] Amino Acid Sequence. Blotting, Western. Calcium-Binding Proteins / genetics. Cell Cycle Proteins / genetics. Cell Line, Tumor. Chromosomes, Human, Pair 16. Cloning, Molecular. DNA Mutational Analysis. Gene Silencing. Hepatitis B / complications. Hepatitis B virus. Humans. Loss of Heterozygosity. Mad2 Proteins. Molecular Sequence Data. RNA Interference. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410446.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / RPGRIP1L protein, human; 0 / Repressor Proteins
  •  go-up   go-down


32. Tan WP, Tan AW, Ee HL, Kumarasinghe P, Tan SH: Melanization in basal cell carcinomas: microscopic characterization of clinically pigmented and non-pigmented tumours. Australas J Dermatol; 2008 Nov;49(4):202-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanization in basal cell carcinomas: microscopic characterization of clinically pigmented and non-pigmented tumours.
  • Clinical and microscopic pigmentation may affect the treatment outcomes in basal cell carcinoma.
  • However, there have not been any in-depth histopathological comparisons between clinically pigmented and non-pigmented basal cell carcinomas with regards to microscopic melanization.
  • The aims of our study were to determine the proportion of pigmented basal cell carcinomas presenting to the National Skin Centre in Singapore, to characterize the histological pattern of melanization and to perform a semi-quantitative analysis of the degree of microscopic melanization of the tumours.
  • Patients with clinical features and histologically confirmed basal cell carcinomas were recruited.
  • Demographic data and clinical characteristics were recorded and basal cell carcinoma sections were examined for histological subtype and pattern of melanization.
  • Twenty-five Chinese patients with 30 basal cell carcinomas were recruited.
  • Three of the five clinically non-pigmented and all of the clinically pigmented basal cell carcinomas had microscopic evidence of melanization.
  • Microscopic melanization in clinically non-pigmented basal cell carcinomas was present only focally or in the centre of the tumour mass.
  • Both groups of basal cell carcinomas may be colonized by melanocytes.
  • Two morphological types of melanocytes, a dendritic and round cell type, were identified.
  • Future research is required to evaluate if the degree of microscopic melanization influences the treatment outcome of basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanocytes / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855781.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


33. Mseddi M, Dammak A, Jellouli M, Ghorbel S, Bouassida S, Marrekchi S, Zahaf A, Turki H: [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)]. Rev Med Liege; 2006 Oct;61(10):724-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)].
  • [Transliterated title] Profil des carcinomes basocellulaires du cuir chevelu secondaires a une radiothérapie pour teigne (a propos de 63 cas).
  • The induction of basal cell carcinoma (BCC) of the scalp by X-ray therapy for tinea capitis is well known.
  • The aim of the study was to specify the epidemiological, clinical and histological characteristics of this disease.
  • It represents the most frequent tumour developing on irradiated scalp.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Head and Neck Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Scalp. Skin Neoplasms / etiology. Tinea Capitis / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209506.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


34. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol; 2006 May;154(5):910-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
  • BACKGROUND: Chemokines and their receptors, well known for their ability to attract leucocytes, also play important roles for tumour progression.
  • OBJECTIVES: To investigate the possible involvement of chemokine receptors in the pathogenesis of cutaneous basal cell carcinoma (BCC).
  • METHODS: We performed an expression analysis of chemokine receptors using a well-characterized human BCC cell line.
  • Upon the finding of CXCR4 expression by BCC, retroviral transduction of BCC cells with the CXCR4 gene was employed to address its functional significance for BCC in vitro and in vivo.
  • RESULTS: We found expression of the CXC chemokine receptor CXCR4 by a human cell line and a subset of tissue samples from BCC, especially in noduloulcerative and sclerosing types.
  • Moreover, xenograft tumour transplants produced by injection of CXCR4-BCC yielded significant tumour progression in nude mice, whereas additional serial injections of CXCR4-blocking peptides resulted in tumour regression.
  • CONCLUSIONS: CXCR4 expression may play a critical role in tumour progression and angiogenesis of certain subtypes of BCC with more aggressive nature, and functional blockade of CXCR4 could be a potential therapeutic strategy for these tumours.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Proliferation. Chemokine CXCL12. Chemokines, CXC / physiology. Disease Progression. Female. Humans. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction. Transduction, Genetic. Transplantation, Heterologous. Tumor Cells, Cultured. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634895.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


35. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Christidis K, Papazoglou G, Antoniades D, Barbatis C: Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland. Oral Oncol; 2005 Sep;41(8):799-805
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland.
  • The study of the expression of cell adhesion molecules (CAMs), E-cadherin, desmoglein-2, beta4-integrin, HCAM (CD44s) and ICAM-1 in Warthin's tumours.
  • Beta4-integrin was strongly expressed in all cell-basement membrane and intercellular contacts of the epithelium, E-cadherin and desmoglein-2 in cell-cell contacts, but not in basal cell-basement membrane connections and on columnar cells' luminal surfaces, HCAM (CD44s) in intercellular contacts of both luminal (mainly), basal cells and also in the periphery of monocytic-lymphocytic stroma, and ICAM-1 was weak to moderate expressed in both luminal and basal epithelial cells and strongly in the germinal lymphocytic centres.
  • CAM expression suggests a bilayered excretory ductal structure of the neoplastic epithelium in Warthin's tumour, as a result of hyperplastic process of the glandular epithelium that interacts with the excessive lymphoid tissue of the stroma.
  • [MeSH-major] Adenolymphoma / metabolism. Cell Adhesion Molecules / metabolism. Integrin beta4 / metabolism. Neoplasm Proteins / metabolism. Parotid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043382.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Desmoglein 2; 0 / Integrin beta4; 0 / Neoplasm Proteins
  •  go-up   go-down


36. Salem A, Phillips JS, Joseph JA, O'Donovan DG, Jani P: Basal cell adenocarcinoma of the ethmoid sinuses. J Laryngol Otol; 2007 Sep;121(9):889-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the ethmoid sinuses.
  • Basal cell adenocarcinoma is a rare and relatively recently characterised malignant salivary gland tumour.
  • Basal cell adenocarcinoma has only been described once before in the ethmoid sinus.
  • We report a case of basal cell adenocarcinoma in the ethmoid sinus, extending into the right orbit and anterior cranial fossa.
  • [MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295935.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Ye D, Ma TY: Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med; 2008 Aug;12(4):1331-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity.
  • The patients with Crohn's disease (CD) have a 'leaky gut' manifested by an increase in intestinal epithelial tight junction (TJ) permeability.
  • Tumour necrosis factor-alpha (TNF-alpha) is a proto-typical pro-inflammatory cytokine that plays a central role in intestinal inflammation of CD.
  • The major aim of this study was to elucidate the cellular and molecular mechanisms that mediate basal and TNF-alpha-induced increase in MLCK gene activity.
  • A p53 binding site located within minimal promoter region was identified as an essential determinant for basal promoter activity.
  • In conclusion, we have identified the minimal MLCK promoter region, essential molecular determinants and molecular mechanisms that mediate basal and TNF-alpha-induced modulation of MLCK promoter activity in Caco-2 intestinal epithelial cells.
  • These studies provide novel insight into the cellular and molecular mechanisms that regulate basal and TNF-alpha-induced modulation of MLCK gene activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363837.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK064165; United States / NIDDK NIH HHS / DK / R0 1-DK-64165-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; EC 2.7.11.18 / Myosin-Light-Chain Kinase
  • [Other-IDs] NLM/ PMC3865676
  •  go-up   go-down


38. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • Nodulocystic lesions were the most common type of tumour, comprising 48% of lesions, and most BCCs were located on the head and neck region.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


39. Macpherson N, Lamrock E, Watt G: Effect of inflammation on positive margins of basal cell carcinomas. Australas J Dermatol; 2010 May;51(2):95-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of inflammation on positive margins of basal cell carcinomas.
  • BACKGROUND/OBJECTIVES: The use of preparations such as imiquimod in the treatment of basal cell carcinoma is well accepted.
  • Imiquimod induces interferon-alpha, other cytokines, antigen-presenting cells and innate immunity, against tumour cells.
  • The current study investigated whether the inflammation induced from a surgical procedure could have a similar effect on removing residual tumour after an excision.
  • METHOD: A retrospective audit was carried out on basal cell carcinoma removed in the Dermatology Clinic of the Royal Newcastle Centre in 2007.
  • The end-point focussed on the features of those tumours which initially had a positive margin, but were found to have no remaining tumour on subsequent excision.
  • These were the location of the basal cell carcinoma excision and the excision type.
  • A larger sample size that encompassed all three factors that affect outcome, that is, the location of lesion, type of lesion and type of excision carried out, would be required in order to make a more definitive statement on protocol change for treatment of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546214.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


40. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Försti A, Kumar R: No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol; 2007 Aug;157(2):375-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
  • BACKGROUND: The MDM2 oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumour suppressor protein.
  • Basal cell carcinoma of the skin (BCC) is one of the most common neoplasms in the world.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Age of Onset. Aged. Aged, 80 and over. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2008 Mar;158(3):636; author reply 636-7 [18076702.001]
  • (PMID = 17553029.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


41. Fadloun A, Kobi D, Pointud JC, Indra AK, Teletin M, Bole-Feysot C, Testoni B, Mantovani R, Metzger D, Mengus G, Davidson I: The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis. Development; 2007 Aug;134(16):2947-58
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis.
  • The TAF4 subunit of transcription factor TFIID was inactivated in the basal keratinocytes of foetal and adult mouse epidermis.
  • Moreover, loss of TAF4 leads to malignant transformation of chemically induced papillomas and the appearance of invasive melanocytic tumours.
  • Together, our results show that TAF4 is an important regulator of keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity.
  • [MeSH-major] Cell Proliferation. Epidermis / metabolism. Keratinocytes / cytology. TATA-Binding Protein Associated Factors / metabolism. TATA-Binding Protein Associated Factors / physiology. Transcription Factor TFIID / metabolism. Transcription Factor TFIID / physiology. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Cell Differentiation / genetics. Female. Genetic Predisposition to Disease. Hair / cytology. Hair / embryology. Hyperplasia / chemically induced. Male. Mice. Mice, Knockout. Nevus, Pigmented / chemically induced. Nevus, Pigmented / genetics. Protein Subunits / physiology. Skin Neoplasms / chemically induced. Skin Neoplasms / pathology. Tretinoin / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626060.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / TAF4 protein, mouse; 0 / TATA-Binding Protein Associated Factors; 0 / Transcription Factor TFIID; 0 / Tumor Suppressor Proteins; 5688UTC01R / Tretinoin
  •  go-up   go-down


42. Caresana G, Giardini R: Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1395-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy-guided surgery in basal cell carcinoma.
  • BACKGROUND: In basal cell carcinoma (BCC), excision margins between 3 and 10 mm, according to site, size, borders, previous treatment and histology, can allow for radical excision in at least 95% of cases.
  • OBJECTIVE: The objective was to ascertain whether dermoscopy can detect more accurately the lateral borders in BCCs than clinical examination alone, and allow us to obtain radical excision in more than 95% of cases with only 2-mm excision margins.
  • RESULTS: In only three cases did surgical excision with 2-mm margins prove to be inadequate; in the remaining 197 cases, the excision margins were tumour-free.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Dermoscopy. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384678.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


43. Rütten A, Hantschke M, Angulo J, Requena L: Clear-cell dermal duct tumour: another distinctive, previously underrecognized cutaneous adnexal neoplasm. Histopathology; 2007 Dec;51(6):805-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell dermal duct tumour: another distinctive, previously underrecognized cutaneous adnexal neoplasm.
  • AIMS: To describe 13 examples of clear cell dermal duct tumour, a neoplasm previously underrecognized in the literature.
  • METHODS AND RESULTS: Thirteen examples of a neoplasm that we have named clear-cell dermal duct tumour were studied histopathologically and immunohistochemically.
  • Histopathologically, all lesions consisted of mostly dermal neoplasms mainly composed of multiple solid aggregations of clear cells involving the dermis.
  • Although the neoplasms were mostly solid, ductal structures were identified in all cases.
  • Epithelial membrane antigen, carcinoembryonic antigen and glial cystic disease fibrillary protein 15 decorated the ductal structures, but neoplastic cells were negative.
  • In contrast to some other clear cell neoplasms of the skin, which may be associated with diabetes mellitus, none of our cases of clear cell dermal duct tumour developed in a diabetic patient.
  • CONCLUSIONS: We consider these neoplasms to be clear cell dermal duct tumours for the following reasons: (i) the neoplasms were mostly composed of multiple solid aggregations of epithelial clear cells;.
  • (iv) small areas of necrosis en masse were seen in some neoplastic aggregations; and (v) the stroma of the neoplasm was scant.
  • [MeSH-major] Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nevus / pathology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042069.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


45. Rieger UM, Kalbermatten DF, Wettstein R, Heider I, Haug M, Pierer G: Marjolin's ulcer revisited--basal cell carcinoma arising from grenade fragments? Case report and review of the literature. J Plast Reconstr Aesthet Surg; 2008;61(1):65-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marjolin's ulcer revisited--basal cell carcinoma arising from grenade fragments? Case report and review of the literature.
  • METHOD: A 79-year-old World War II veteran developed basal cell carcinoma (BCC) at the site of a war wound.
  • The tumour developed in relation to several metal grenade fragments.
  • With a disease-free interval of 61 years between injury and onset of complications the patient had one of the longest latency periods of tumour development described so far.
  • Considering the long period of latency between injury and tumour development we suggest grenade injury with left fragments in soft tissue to be a new origin of Marjolin's ulcer.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Cicatrix / complications. Skin Neoplasms / etiology. Skin Ulcer / etiology. Wounds, Gunshot / complications

  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068654.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 42
  •  go-up   go-down


46. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Clinical examination revealed a pale lobulated tumour without skin involvement.
  • The tumour was excised.
  • Three years later a small polypoid tumour developed in the inferior fornix of the same eye.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Raasch BA, Buettner PG, Garbe C: Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol; 2006 Aug;155(2):401-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: histological classification and body-site distribution.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer worldwide in white-skinned populations.
  • For all histological subtypes and both genders relative tumour density was highest for the face, followed by the neck.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882181.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Guarino M: Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol; 2007;39(12):2153-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition and tumour invasion.
  • There is increasing evidence pointing to a role of epithelial-mesenchymal transition by which tumour cells would weaken E-cadherin-dependent intercellular adhesion and enhance motility, thus becoming able to penetrate into surrounding tissues.
  • The activated tissue microenvironment at the advancing tumour front seems to provide the appropriate stimuli for triggering this change.
  • The binding of growth factors and extracellular matrix molecules to tumour cell membrane receptors generates cascades of intracellular signals that could ultimately promote the down-regulation of E-cadherin and the activation of the cytoskeleton.
  • Therefore, cells lose intercellular junctions and emanate cytoplasmic extensions that protrude from the basal surface into the stromal compartment through interruptions of the basement membrane.
  • These protrusions establish new contacts with the interstitial matrix and, finally, the contraction of the cytoskeleton allows cell translocation into the stroma.
  • Thus, in addition to increasing our knowledge of tumour invasion biology, studying epithelial-mesenchymal transition will, in the future, offer novel opportunities to define clinical parameters and pharmacological treatment.
  • [MeSH-major] Epithelium / pathology. Mesoderm / pathology. Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Movement / physiology. Extracellular Matrix / metabolism. Humans. Models, Biological. Neoplasm Invasiveness. rho GTP-Binding Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825600.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.5.2 / rho GTP-Binding Proteins
  • [Number-of-references] 29
  •  go-up   go-down


49. Wetzig T, Kendler M, Maschke J, Paasch U, Simon JC: No clinical benefit of preoperative fluorescence diagnosis of basal cell carcinoma localized in the H-zone of the face. Br J Dermatol; 2010 Jun;162(6):1370-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No clinical benefit of preoperative fluorescence diagnosis of basal cell carcinoma localized in the H-zone of the face.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin carcinoma.
  • Fluorescence diagnosis (FD) has been suggested as a promising method for noninvasive detection of subclinical tumour cell dissemination in BCC.
  • The tumour area was determined 3 h after application of methyl aminolaevulinate by inspection and photographic documentation (CD) and FD.
  • The tumour areas as determined by FD, CD and histology were superimposed to map the entire lateral tumour margin.
  • RESULTS: The tumour area could be visualized by FD in 24 of 26 patients.
  • The mean tumour area as determined by FD was significantly smaller than the tumour area as determined by CD [80 mm(2) , 95% confidence interval (CI) 50-110 mm(2) vs. 101 mm(2) , 95% CI 76-125 mm(2) ; P < 0·012].
  • The superimposition of FD and histology showed in 10 of 26 patients a complete detection of the tumour margin by FD; thus sensitivity of FD was calculated as 38·5%.
  • In only three of 26 patients FD revealed a tumour extent greater than determined by CD.
  • CONCLUSIONS: On aggregate, this study suggests that preoperative FD of nodular BCC localized in the H-zone offers no additional benefit to define subclinical tumour infiltration compared with CD alone.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Facial Neoplasms / diagnosis. Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20302577.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. de Zwaan SE, Haass NK: Genetics of basal cell carcinoma. Australas J Dermatol; 2010 May;51(2):81-92; quiz 93-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of basal cell carcinoma.
  • Basal cell carcinoma is the most common human malignancy in populations of European origin, and Australia has the highest incidence of basal cell carcinoma in the world.
  • Mutations of the patched 1 gene (PTCH1) lead to basal cell carcinoma predisposition in Gorlin syndrome.
  • PTCH1 is part of the hedgehog signalling pathway, and derangements within this pathway are now known to be important in the carcinogenesis of many different cancers including sporadic basal cell carcinoma.
  • The molecular biology of the hedgehog pathway is discussed, and mouse models of basal cell carcinoma based on this pathway are explored.
  • New developments in non-surgical treatment of basal cell carcinoma are based on this knowledge.
  • Other genes of importance to basal cell carcinoma development include the tumour suppressor gene P53 and the melanocortin-1 receptor gene.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / therapy. Disease Models, Animal. Genetic Predisposition to Disease. Hedgehog Proteins / genetics. Humans. Mice. Mutation. Receptor, Melanocortin, Type 1 / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546211.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Protein p53; 0 / patched receptors
  •  go-up   go-down


51. Azzam C, Arrese JE, Jacquemin D, Calteux N, Piérard GE: [Pedunculated and pigmented basal cell carcinoma: an unusual presentation]. Rev Med Liege; 2006 Sep;61(9):614-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pedunculated and pigmented basal cell carcinoma: an unusual presentation].
  • Basal cell carcinomas (BCC) are the most common malignant neoplasms in humans.
  • These cancers are classified according to their histological and clinical characteristics which exhibit distinct malignant behaviours.
  • It is important to be aware of the different clinical presentations both for the accurate diagnosis and tumour management.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112160.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


52. Walker P, Hill D: Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol; 2006 Feb;47(1):1-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of basal cell carcinomas using standard postoperative histological assessment.
  • SUMMARY Surgical treatment of basal cell carcinomas using postoperative histological assessment is routinely practised in Australia.
  • The tumour border is then identified and a margin added.
  • Tumour recurrence is rare (less than 2% at 5 years) if the tumour is clear of the surgical margin.
  • The visualized histological margin required to ensure complete excision varies with histological technique and tumour properties.
  • Tumour recurrence averages 38% when the histological margin is involved.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Education, Medical, Continuing. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Reoperation. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405477.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 95
  •  go-up   go-down


53. Salas-Garcia I, Fanjul-Velez F, Ortega-Quijano N, Arce-Diego JL: Photodynamic effects on basal cell carcinoma with topical Photosensitizer. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:2739-42
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic effects on basal cell carcinoma with topical Photosensitizer.
  • However, some cases of basal cell carcinoma show tumour persistence.
  • In this work we present a PDT model that tries to predict the photodynamic effect on the skin affected by a basal cell carcinoma with a topically administered photosensitizer.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21096212.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; S88TT14065 / Oxygen
  •  go-up   go-down


54. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ: alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res; 2008 May 1;68(9):3295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
  • Basal cell carcinoma (BCC) is the most prevalent cancer in the Western world and its incidence is increasing.
  • These cells expressed alpha v beta 6 and were invasive, although inhibition of alpha v beta 6 had no direct effect on cell invasion.
  • Paracrine secretion of hepatocyte growth factor/scatter factor by these myofibroblasts promoted c-Met-dependent tumor invasion in both Transwell and three-dimensional organotypic assays.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Basal Cell / pathology. Integrins / physiology. Skin Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Cell Movement / genetics. Cells, Cultured. Hepatocyte Growth Factor / metabolism. Humans. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Kruppel-Like Transcription Factors / metabolism. Mink. Neoplasm Invasiveness. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-met / metabolism. RNA, Small Interfering / pharmacology. Transcription Factors / genetics. Transcription Factors / metabolism. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451156.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Integrins; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / integrin alphavbeta6; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


55. de Giorgi V, Massi D, Sestini S, Alfaioli B, Carelli G, Carli P: Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report. Br J Dermatol; 2005 Apr;152(4):787-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report.
  • The most common association, basal cell carcinoma (BCC) and naevus, is very difficult to diagnose clinically.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840116.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • All incompletely excised lesions whether or not re-excised were excluded.
  • The median interval to recurrence was 41 months (4 months-8 years 10 months), with median lateral clearance margin around the primary tumour of 2 mm (0.3-6.8 mm).
  • The median lateral clearance margin around the primary tumour was 4.1 mm (0.8-5.8 mm).
  • Two thirds of possible and probable recurrences occurred in the temple and forehead, although these sites represented only 22% of all lesions, which may rather suggest new lesions in an area of field change as opposed to residual disease.
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Lo Muzio L: Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis; 2008;3:32
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
  • Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary condition characterized by a wide range of developmental abnormalities and a predisposition to neoplasms.
  • Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
  • [MeSH-major] Basal Cell Nevus Syndrome
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / epidemiology. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Bone and Bones / abnormalities. Bone and Bones / radiography. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Child. Female. Humans. Male. Medulloblastoma / epidemiology. Medulloblastoma / genetics. Medulloblastoma / pathology. Odontogenic Cysts / epidemiology. Odontogenic Cysts / genetics. Odontogenic Cysts / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23 [14616807.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1236-40 [14725671.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] J Dermatolog Treat. 2004 Apr;15(2):120-1 [15204165.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):441 [15459969.001]
  • [Cites] Arch Fr Pediatr. 1968 Nov;25(9):1083-93 [5728392.001]
  • [Cites] Med Hist. 1969 Jul;13(3):294-7 [4893629.001]
  • [Cites] J Neurosurg. 1971 Nov;35(5):577-84 [5000945.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):140-8 [4950929.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jan;84(1):107-12 [1251730.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):100-2 [758369.001]
  • [Cites] Cancer. 1979 Dec;44(6):2294-305 [509397.001]
  • [Cites] Br J Oral Surg. 1979 Nov;17(2):135-46 [298837.001]
  • [Cites] Hautarzt. 1981 Sep;32(9):455-8 [7275582.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Ann Neurol. 1982 Apr;11(4):372-6 [7103417.001]
  • [Cites] Wien Klin Wochenschr. 1982 Sep 3;94(16):430-4 [7147982.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):178-9 [6855699.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):210-2 [6707662.001]
  • [Cites] Can Med Assoc J. 1985 May 1;132(9):1037-8 [3986729.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):700-6 [3951494.001]
  • [Cites] J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1023-30 [3537024.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70 [3584581.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):901-4 [3655059.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):528-31 [3676586.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):309-14 [9096762.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):519-22 [17139991.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):133-6 [16977487.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):202-3 [16780502.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4 Suppl):315-20 [17328283.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):360-2 [17826543.001]
  • [Cites] J Drugs Dermatol. 2007 Sep;6(9):910-4 [17941362.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):459-66 [17703323.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):366-73 [9339279.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Laryngoscope. 1998 Feb;108(2):280-3 [9473082.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):291-7 [9931336.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Dermatologica. 1963;126:106-23 [13954184.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):716-8 [15586876.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Arch Dermatol Res. 2005 Jan;296(7):303-8 [15565302.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):665-8 [15684600.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322-3 [15712338.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Genet Med. 2005 Nov-Dec;7(9):611-9 [16301862.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Echocardiography. 2006 Jan;23(1):79-80 [16412193.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Ann Dermatol Venereol. 2006 Feb;133(2):117-23 [16508594.001]
  • [Cites] Tex Heart Inst J. 2006;33(1):88-90 [16572881.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):e16 [16582078.001]
  • [Cites] Tumour Biol. 2006;27(4):175-80 [16675912.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):548-53 [16909134.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):287-90 [11896785.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Am J Med Genet. 2002 Jul 15;110(4):400-3 [12116218.001]
  • [Cites] Mol Genet Metab. 2002 May;76(1):57-61 [12175781.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):233-4 [12204003.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):569-72 [12459530.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):47-50 [12604725.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12):913-4 [12607884.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):1093-5 [12712116.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S64-6 [12734479.001]
  • [Cites] Pediatr Neurol. 2003 Mar;28(3):231-4 [12770681.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):390-2 [12756507.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):575-80 [17019435.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1084-6 [17021131.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S86-9 [17052541.001]
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2625-30 [16906569.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):790-4 [10782799.001]
  • [Cites] Brain Dev. 2000 Jun;22(4):272-4 [10838118.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):140-6 [10868476.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • [Cites] Cutis. 2000 Jul;66(1):35-8 [10916689.001]
  • [Cites] Arch Dermatol Res. 2000 Sep;292(9):475-6 [11000293.001]
  • [Cites] Br Dent J. 2001 Apr 14;190(7):349-50 [11338037.001]
  • [Cites] J Dermatol Sci. 2001 Sep;27(1):21-6 [11457640.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):727-30 [3480489.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] J Am Dent Assoc. 1988 Jun;116(7):887-9 [3164743.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Presse Med. 1988 Nov 26;17(42):2247-50 [2974590.001]
  • [Cites] Dentomaxillofac Radiol. 1987;16(2):99-103 [3333752.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jun;47(6):629-33 [2656943.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):64-6 [2045256.001]
  • [Cites] Pediatr Radiol. 1991;21(3):234-5 [2047170.001]
  • [Cites] Genet Couns. 1990;1(3-4):273-7 [2098052.001]
  • [Cites] Am J Med Genet. 1991 Aug 1;40(2):206-10 [1910262.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1494-8 [1540957.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):255-62 [1570241.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):441-7 [1409143.001]
  • [Cites] Cesk Pediatr. 1993 Mar;48(3):129-32 [8495514.001]
  • [Cites] Dermatology. 1993;186(4):311-2 [8513207.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):760-7 [8352281.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):447-8 [8012356.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):272-81 [8042672.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Lancet. 1994 Aug 13;344(8920):477 [7914587.001]
  • [Cites] Bol Asoc Med P R. 1993 Jan-Mar;85(1-3):24-6 [8060441.001]
  • [Cites] Prenat Diagn. 1994 Aug;14(8):725-7 [7991513.001]
  • [Cites] Genomics. 1994 Aug;22(3):505-11 [8001963.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Pediatr Dermatol. 1994 Dec;11(4):323-6 [7899182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):361-8 [7795971.001]
  • [Cites] Br J Radiol. 1995 Jun;68(810):596-9 [7627481.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):94-5 [8546496.001]
  • [Cites] Neurology. 1996 Feb;46(2):574-6 [8614540.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Br J Ophthalmol. 1996 Apr;80(4):378 [8703894.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Histopathology. 1996 Sep;29(3):247-52 [8884353.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • (PMID = 19032739.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 164
  • [Other-IDs] NLM/ PMC2607262
  •  go-up   go-down


58. Hüsler R, Schlittler FL, Kreutziger J, Streit M, Banic A, Schöni-Affolter F, Hunger RE, Constaninescu MA: Staged surgical therapy of basal cell carcinoma of the head and neck region: an evaluation of 500 procedures. Swiss Med Wkly; 2008 Dec 13;138(49-50):746-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staged surgical therapy of basal cell carcinoma of the head and neck region: an evaluation of 500 procedures.
  • QUESTIONS UNDER STUDY / PRINCIPLES: The surgical therapy of basal cell carcinoma (BCC) is especially demanding in the facial area.
  • SST was performed in two stages in 43.7%, in three stages in 12.9% and in four or more stages in 2.7%, depending on the type of tumour and the patient's pretreatment status.
  • CONCLUSIONS: The staged surgical therapy of basal cell carcinoma evaluated here offers a series of advantages in respect of patient comfort and safety and economy, while allowing precise histological safety with low infection rates and reliable long-term results.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Swiss Med Wkly. 2010 Jan 9;140(1-2):31-2; author reply 32 [20669073.001]
  • (PMID = 19130328.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Micke P, Ostman A: Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets; 2005 Dec;9(6):1217-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy.
  • Fibroblasts, often termed myofibroblasts or cancer-associated fibroblasts (CAFs), represent the most abundant cell type in the tumour stroma.
  • The demonstrated tumour-promoting capacities of CAFs has increased the interest to exploit them as drug targets for anticancer therapy.
  • Although single factors, such as platelet-derived growth factor, transforming growth factor-beta1, hepatocyte growth factor and matrix metalloproteinases have been identified as mediators in the fibroblast tumour interaction, the morphological and functional differences of CAFs compared with their normal counterparts are only incompletely understood.
  • Recently, novel global methods for gene expression profiling were applied to comprehensively characterise CAFs from breast, pancreas, colon and basal cell cancer in their in situ environment.
  • The analysis of different CAF preparations revealed regulated genes that were previously not described in the tumour-stroma context.
  • Additionally, besides a few striking overlaps, the comparison of the gene lists indicates a high level of heterogeneity in the expression pattern of CAFs from different tumour types.
  • Together, these studies emphasise the importance of cross-talk between stromal and malignant cells of the tumour.
  • It is likely that the continued characterisation of this interaction, and the molecular identification of key mediators, will provide insights into tumour biology and suggest novel therapeutic options.
  • [MeSH-major] Fibroblasts / metabolism. Fibroblasts / pathology. Gene Expression Regulation, Neoplastic. Gene Targeting / methods. Neoplasms / metabolism. Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Proliferation. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300472.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 147
  •  go-up   go-down


60. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • This neoplasm is often located on the limbs.
  • The histopathological diagnosis is difficult, mainly because this tumour is exceptional.
  • RESULTS: Histopathologic findings showed an asymmetrical deep dermal tumour with a cribriform pattern.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


61. McCarthy A, Savage K, Gabriel A, Naceur C, Reis-Filho JS, Ashworth A: A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol; 2007 Mar;211(4):389-98
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model of basal-like breast carcinoma with metaplastic elements.
  • Breast cancers arising in carriers of germline BRCA1 mutations frequently have a basal-like phenotype.
  • Basal-like cancers are characterized by high histological grade, central necrotic areas, foci with metaplastic differentiation, lack of hormone receptor and HER2 (ErbB2) expression, and consistent positivity for basal markers, including CK5/6, CK14, and EGFR.
  • Transgenic expression of Cre recombinase in the mammary gland of these mice results in deletion of exons encoding the C-terminus of Brca1 and leads to tumour formation when combined with heterozygosity for a p53 mutation.
  • These metaplastic elements consisted of neoplastic spindle cells or squamous cell differentiation in the form of keratin pearls or individual cell keratinization.
  • Immunohistochemical analysis revealed expression of basal-like markers in all cases.
  • The tumour phenotype generated in our mouse model was compared with published data on human basal-like breast carcinomas and also with metaplastic breast cancers with a basal-like phenotype; the comparison showed that we have generated a mouse model of basal-like breast cancer, which should prove useful in testing new and targeted treatments for this type of breast cancer.
  • [MeSH-major] Mammary Neoplasms, Experimental / genetics. Neoplasm Metastasis / genetics
  • [MeSH-minor] Animals. BRCA1 Protein / deficiency. BRCA1 Protein / genetics. Carcinoma, Basal Cell / genetics. Cell Differentiation / genetics. Creatine / genetics. Female. Genes, p53 / genetics. Heterozygote. Immunohistochemistry / methods. Keratin-14 / genetics. Lactoglobulins / genetics. Mammary Glands, Animal / pathology. Mice. Mice, Inbred C57BL. Mutation / genetics. Promoter Regions, Genetic / genetics. Receptor, Epidermal Growth Factor / genetics. Receptors, Estrogen / genetics. Transgenes / genetics


62. Saetta AA, Aroni K, Stamatelli A, Lazaris AC, Patsouris E: Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma. Arch Dermatol Res; 2005 Sep;297(3):99-107
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma.
  • Microsatellite instability (MSI) constitutes an alternative-to the chromosomal instability-pathway of carcinogenesis for certain tumour types with prognostic and therapeutic significance for the respective patients.
  • The role of MSI in basal cell carcinoma (BCC) has not been clearly delineated yet. p53 gene as a target for ultraviolet radiation-induced mutations may enhance genomic instability in BCC, with loss of its function.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carrier Proteins / metabolism. MutS Homolog 2 Protein / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Female. Gene Expression Regulation, Neoplastic. Genomic Instability / genetics. Humans. Male. Microsatellite Repeats / genetics. Protein Transport. Skin Neoplasms / genetics. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012876.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


63. Herschkowitz JI, He X, Fan C, Perou CM: The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res; 2008;10(5):R75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
  • One of these groups, the basal-like subtype, is poorly differentiated, highly metastatic, genomically unstable, and contains specific genetic alterations such as the loss of tumour protein 53 (TP53).
  • The loss of the retinoblastoma tumour suppressor encoded by the RB1 locus is a well-characterised occurrence in many tumour types; however, its role in breast cancer is less clear with many reports demonstrating a loss of heterozygosity that does not correlate with a loss of RB1 protein expression.
  • METHODS: We used gene expression analysis for tumour subtyping and polymorphic markers located at the RB1 locus to assess the frequency of loss of heterozygosity in 88 primary human breast carcinomas and their normal tissue genomic DNA samples.
  • RESULTS: RB1 loss of heterozygosity was observed at an overall frequency of 39%, with a high frequency in basal-like (72%) and luminal B (62%) tumours.
  • These tumours also concurrently showed low expression of RB1 mRNA. p16INK4a was highly expressed in basal-like tumours, presumably due to a previously reported feedback loop caused by RB1 loss.
  • CONCLUSIONS: These results suggest that the functional loss of RB1 is common in basal-like tumours, which may play a key role in dictating their aggressive biology and unique therapeutic responses.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Cell Genet. 1992;60(3-4):190-3 [1354594.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2991-4 [1581913.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5816-20 [7954407.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6078-82 [7954450.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):503-6 [7777060.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):15-20 [8686738.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):71-5 [9495362.001]
  • [Cites] Oncogene. 1998 Jul 16;17(2):199-205 [9674704.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1661-8 [9862580.001]
  • [Cites] Mol Med. 1998 Dec;4(12):807-22 [9990866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2952-7 [10077618.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4059-66 [15899795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8561-6 [15939874.001]
  • [Cites] Clin Chim Acta. 2005 Aug;358(1-2):75-80 [15921673.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9155-8 [16230372.001]
  • [Cites] BMC Genet. 2005;6:53 [16269091.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):63-70 [16540733.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1656-64 [16505416.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R23 [16626501.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):218-28 [17160137.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Mol Cancer. 2007;6:7 [17233903.001]
  • [Cites] Mol Diagn Ther. 2007;11(1):63-70 [17286451.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):811-5 [17700700.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2777-87 [10914724.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Mol Carcinog. 2000 Nov;29(3):151-8 [11108660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6307-18 [17452985.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):479-91 [17996651.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2199-209 [18381962.001]
  • [Cites] Hum Mol Genet. 2008 May 15;17(10):1363-72 [18211953.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Dis Markers. 2001;17(2):99-109 [11673656.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):285-8 [12068296.001]
  • [Cites] Hum Mutat. 2002 Nov;20(5):408 [12402348.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):577-83 [12461615.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Am J Hum Genet. 2003 Feb;72(2):253-69 [12541220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):64-71 [14729609.001]
  • [Cites] Cancer Cell. 2004 May;5(5):489-500 [15144956.001]
  • [Cites] Science. 1988 Jul 8;241(4862):218-21 [3388033.001]
  • [Cites] Science. 1988 Oct 14;242(4876):263-6 [3175651.001]
  • [Cites] Oncogene. 1989 Jun;4(6):725-9 [2543943.001]
  • [Cites] Oncogene. 1993 Aug;8(8):2127-33 [8336939.001]
  • (PMID = 18782450.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / R01 CA101227
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2614508
  •  go-up   go-down


64. Demirtaşoglu M, Ilknur T, Lebe B, Kuşku E, Akarsu S, Ozkan S: Evaluation of dermoscopic and histopathologic features and their correlations in pigmented basal cell carcinomas. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):916-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of dermoscopic and histopathologic features and their correlations in pigmented basal cell carcinomas.
  • BACKGROUND: Because of their clinical similarities, pigmented basal cell carcinomas (BCCs) can be confused with melanocytic pigmented lesions especially with melanoma.
  • Histopathologic correlations of dermoscopic features of BCCs and the localization of pigment accumulation in tumour mass were investigated.
  • It was histopathologically determined that pigmentation is found within the tumour mass as well as in the tumour stroma and in the hyperplastic epidermal melanocytes.
  • In conclusion, dermoscopy can be described as a valuable tool for the diagnosis of pigmented basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922937.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Malik V, Goh KS, Leong S, Tan A, Downey D, O'Donovan D: Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit. J Plast Reconstr Aesthet Surg; 2010 Dec;63(12):2057-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit.
  • BACKGROUND: Basal cell carcinomas are the most prevalent of all skin cancers worldwide and form the majority of the surgical workload for most modern cutaneous malignancy centres.
  • Primary surgical removal of basal cell carcinomas remains the gold standard of treatment but, despite almost two centuries of surgical experience, rates of incomplete surgical excision of up to 50% are still reported.
  • The aim of this study was to assess, quantify and perform comparative analysis of the outcomes and predictive factors of consecutive primarily-excised basal cell carcinomas in a tertiary centre over a six-year period.
  • METHODS: Retrospective audit was conducted on all patients who underwent surgical excision of basal cell carcinomas from January 2000 to December 2005.
  • Assessment parameters included patient biographics, tumour management differences and detailed histopathological analysis of tumour margins and subtypes.
  • RESULTS: One thousand eight hundred and thirty two basal cell carcinomas were excised from 1329 patients over the designated time period.
  • CONCLUSIONS: Overall basal cell carcinomas excision rates compared favourably with international reported standards but attention to a variety of surgical and histological risk factors may improve this further.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cheek. Female. Humans. Male. Middle Aged. Nose Neoplasms / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20226750.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Wettstein R, Erba P, Farhadi J, Kalbermatten DF, Arnold A, Haug M, Pierer G: Incomplete excision of basal cell carcinoma in the subunits of the nose. Scand J Plast Reconstr Surg Hand Surg; 2008;42(2):92-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma in the subunits of the nose.
  • Reconstructive procedures after resection of nasal basal cell carcinoma (BCC) vary depending on the subunit involved.
  • This, however, was not the result of poor estimation of the extent of the tumour and reluctance to excise more challenging areas widely for reconstruction, but to the method chosen to eradicate the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335353.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Gupta G, Singh R, Shanmugasamy K, Kotasthane DS, Kotasthane VD: Basal cell adenocarcinoma in the tongue: an unusual presentation. Clin Med Insights Oncol; 2010 Nov 21;4:127-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma in the tongue: an unusual presentation.
  • We present a case of basal cell adenocarcinoma (BCAC) in the tongue in a 65-year old male.
  • Hematoxylin and eosin staining showed tumour composed of variable sized and shaped, nests and sheets of basaloid epithelial cells having hyperchromatic to vesicular nuclei.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151583.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999957
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / minor salivary gland / tongue
  •  go-up   go-down


68. Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I: Pharmacological treatments for basal cell carcinoma. Drugs; 2007;67(6):915-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological treatments for basal cell carcinoma.
  • Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer, and its incidence continues to rise.
  • Current management options are numerous and focus on tumour eradication while maximising cosmetic and functional capacity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17428108.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 167
  •  go-up   go-down


69. Zribi H, Cherif F, Zakraoui H, Cheikhrouhou R, Mokni M, Ben Osman Dhahri A: [Cryosurgery for nose basal cell carcinoma. Series of 17 tumors]. Tunis Med; 2006 Aug;84(8):473-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryosurgery for nose basal cell carcinoma. Series of 17 tumors].
  • [Transliterated title] Place de la cryochirurgie dans le traitement des carcinomes basocellulaires du nez. A propos d'une série de 17 tumeurs.
  • Basal cell carcinoma (BCC) is the most common malignant tumour of the skin frequently located on the head and chiefly on the nose.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cryosurgery. Nose / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175686.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


70. Gambichler T, Skrygan M, Hyun J, Bechara F, Tomi NS, Altmeyer P, Kreuter A: Cytokine mRNA expression in basal cell carcinoma. Arch Dermatol Res; 2006 Aug;298(3):139-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine mRNA expression in basal cell carcinoma.
  • The aim of the present study was to investigate the mRNA expression of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-8 in biopsy specimens of basal cell carcinoma (BCC), and to compare the results with the mRNA levels of non-lesional skin of BCC patients and healthy subjects.
  • In accordance with previous studies our data suggest a role for IL-6 and IL-8 in the development and/or progression of BCC, since mRNA expression of both CKs are significantly increased in tumour tissue.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cytokines / genetics. RNA, Messenger / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826314.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger
  •  go-up   go-down


71. Galletly NP, McGinty J, Dunsby C, Teixeira F, Requejo-Isidro J, Munro I, Elson DS, Neil MA, Chu AC, French PM, Stamp GW: Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br J Dermatol; 2008 Jul;159(1):152-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin.
  • OBJECTIVES: To establish whether FLIM of skin autofluorescence can provide useful contrast between basal cell carcinomas (BCCs) and surrounding uninvolved skin.
  • CONCLUSIONS: We therefore believe that FLIM has a potential future clinical role in imaging BCCs for rapid and noninvasive tumour delineation and as an aid to determine adequate excision margins with best preservation of normal tissue.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Diagnostic Imaging / methods. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Fluorescence. Humans. Male. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460029.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


72. Bøgelund FS, Philipsen PA, Gniadecki R: Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol; 2007;87(4):330-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the recurrence rate of basal cell carcinoma.
  • The aim of this retrospective survey was to determine recurrence rates after treatment of basal cell carcinomas in a single academic dermatology department.
  • A total of 1016 patients with 1593 histologically verified basal cell carcinomas (n=1212 primary and n=381 relapsing) were included.
  • Tumour localization, T-stage and the method of treatment were significant predictors of the risk of recurrence (forward Cox regression, p <0.001).
  • The relapse rate for primary basal cell carcinomas on the scalp was highest (odds ratio (OR)=2.8, 95% confidence interval (CI) 1.5-5.3).
  • T2 and T3 tumours showed a 2- and 3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas.
  • Recurrent basal cell carcinomas had a higher relapse rate than primary lesions (OR=1.8, CI=1.4-2.2).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598036.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


73. Ba K, Li X, Wang H, Liu Y, Zheng G, Yang Z, Li M, Shimizutani K, Koseki T: Correlation between imaging features and epithelial cell proliferation in keratocystic odontogenic tumour. Dentomaxillofac Radiol; 2010 Sep;39(6):368-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between imaging features and epithelial cell proliferation in keratocystic odontogenic tumour.
  • OBJECTIVES: this study was undertaken to investigate the relationship between radiographic appearance and epithelial cell proliferations in keratocystic odontogenic tumours (KCOTs).
  • RESULTS: the radiographic presentation of KCOT was divided into four types: unilocular, multilocular, multiple and naevoid basal cell carcinoma syndrome (NBCCS).
  • The solitary KCOT seems less biologically aggressive and it should be classified as a cyst rather than a tumour.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Keratins. Ki-67 Antigen / analysis. Male. Middle Aged. Odontogenic Cysts / metabolism. Odontogenic Cysts / pathology. Odontogenic Cysts / radiography. Radiography, Panoramic. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] J Contemp Dent Pract. 2000 Feb 15;1(2):60-74 [12167890.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Aug;98(2):232-6 [15316550.001]
  • [Cites] Ann R Coll Surg Engl. 1967 May;40(5):306-36 [6024922.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] Pediatr Radiol. 1991;21(8):584-7 [1815182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] J Oral Pathol Med. 1995 Oct;24(9):393-7 [8537911.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] J Periodontol. 1997 Mar;68(3):306-11 [9100207.001]
  • [Cites] Schweiz Monatsschr Zahnmed. 2005;115(2):110-28 [15771334.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • (PMID = 20729187.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC3520243
  •  go-up   go-down


74. Fan YS, Carr RA, Sanders DS, Smith AP, Lazar AJ, Calonje E: Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma. Histopathology; 2007 Jul;51(1):80-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
  • AIMS: There is considerable overlap between the histological features of sebaceoma and basal cell carcinoma (BCC).
  • The aim of this study was to describe the immunohistochemical reactivity of the cells in sebaceoma to Ber-EP4 and epithelial membrane antigen (EMA) and investigate the utility of this panel to differentiate sebaceoma from basal cell carcinoma.
  • A single case exhibited focal weak Ber-EP4 staining, predominantly in mature sebocytes and in < 10% of the tumour cells.
  • We reviewed the immunoreactivity of 51 cases of nodular BCCs and found moderate or strong BerEP4 expression in all cases with never less than 20% of the tumour staining.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Mucin-1 / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593083.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / human epithelial antigen-125
  •  go-up   go-down


75. Erba P, Farhadi J, Wettstein R, Arnold A, Harr T, Pierer G: Morphoeic basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg; 2007;41(4):184-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoeic basal cell carcinoma of the face.
  • The morphoeic (or sclerosing) basal cell carcinoma (mBCC) is the most aggressive subtype, as it spreads into the dermis beyond the clinically visible or palpable borders, making complete excision difficult.
  • The estimation of tumour margins and the treatment of mBCC requires substantial clinical experience.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701732.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Khandwala M, Penmetsa BR, Dey S, Schofield JB, Jones CA, Podoleanu A: Imaging of periocular basal cell carcinoma using en face optical coherence tomography: a pilot study. Br J Ophthalmol; 2010 Oct;94(10):1332-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of periocular basal cell carcinoma using en face optical coherence tomography: a pilot study.
  • AIM: To use en face optical coherence tomographic (OCT) imaging to identify features of tumour tissue and their correlation with histopathologic findings and to assess the effect of different wavelengths and resolutions of OCT in identifying tumour boundaries and features.
  • METHODS: Excision specimens of consecutive biopsy-proven periocular basal cell carcinomas (BCCs) (n=8) were assessed by OCT, performing in vitro cross-section and en face scans of the tissues.
  • RESULTS: Three common features of tumour tissue were observed in all the three systems:.
  • We compared the three systems based on their ability to pick up the three above-mentioned tumour features.
  • CONCLUSION: En face OCT imaging has the potential to identify tumour tissue from healthy tissue.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Orbital Neoplasms / pathology. Tomography, Optical Coherence / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516143.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer; 2010 Mar 2;102(5):815-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
  • BACKGROUND: The expression of side-population (SP) cells and their relation to tumour-initiating cells (T-ICs) have been insufficiently studied in breast cancer (BC).
  • We therefore evaluated primary cell cultures derived from patients and a panel of human BC cell lines with luminal- or basal-molecular signatures for the presence of SP and BC stem cell markers.
  • RESULTS: The SP was more prevalent in the luminal subtype of BC compared with the basal subtype.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Insulin-Like Growth Factor Binding Proteins / metabolism. Neoplasm Proteins / metabolism. Neoplastic Stem Cells / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Blotting, Western. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Mice. Mice, Inbred NOD. Mice, Nude. Mice, SCID. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Trastuzumab. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Dev Biol. 2006;6:20 [16672070.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7245-52 [16849573.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1223-33 [17406367.001]
  • [Cites] Mol Cell Biochem. 2007 Dec;306(1-2):201-12 [17660947.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3349-56 [18056989.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] Clin Exp Metastasis. 2008;25(5):549-57 [18386134.001]
  • [Cites] Oncogene. 2008 Oct 16;27(47):6120-30 [18591932.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1302-13 [19190339.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1416-28 [19190349.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2010-21 [19276287.001]
  • [Cites] PLoS Biol. 2009 Jun 2;7(6):e1000121 [19492080.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 16;281(1):25-31 [11178955.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):329-35 [11208823.001]
  • [Cites] Oncogene. 2001 Jun 14;20(27):3497-505 [11429696.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1068-74 [11948115.001]
  • [Cites] Mol Cancer Ther. 2002 Apr;1(6):417-25 [12477054.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 [12529347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Mol Pharmacol. 2003 Dec;64(6):1452-62 [14645676.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):741-56 [14701746.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):802-20 [15120036.001]
  • [Cites] Exp Cell Res. 2004 Aug 1;298(1):144-54 [15242769.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6949-54 [2208160.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):327-33 [9467958.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):89-96 [15681479.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1008s-1012s [16467117.001]
  • [Cites] Laryngoscope. 2006 Mar;116(3):401-6 [16540898.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):524-33 [16415123.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354 [16585151.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5007-11 [16707421.001]
  • [Cites] Blood. 2006 Jul 15;108(2):678-84 [16543472.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Nov;3(11):621-32 [17080180.001]
  • (PMID = 20145614.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Neoplasm Proteins; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2833247
  •  go-up   go-down


78. Shiran MS, Tan GC, Sabariah AR, Rampal L, Phang KS: p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions. Med J Malaysia; 2007 Mar;62(1):36-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions.
  • The diagnosis of prostatic carcinoma (Pca) on routine biopsies may be challenging, and to date the commonly used marker to distinguish prostate carcinoma from benign prostatic lesions has been High Molecular Weight-Cytokeratin (HMW-CK).
  • However, the antigen of HMW-CK is susceptible to the effect of formalin fixation and causes frequent loss or patchy staining in the obviously benign glands.
  • More recently, antibodies to p63 have been reported to be more sensitive than HMW-CK for the detection of prostatic basal cells. p63, a homologue of tumour suppressor gene p53, is essential for prostate development and is selectively expressed in the nuclei of basal cells of normal prostate glands.
  • The objective of this study is to compare the sensitivity and specificity of HMW-CK and p63 in distinguishing prostatic carcinomas from benign prostatic lesions, as well as determining their positive predictive values.
  • Seventy-two cases from HUKM (comprising 29 prostatic carcinomas and 43 benign prostatic hyperplasias) were stained for both HMW-CK and p63.
  • The sensitivity of p63 and HMW-CK in identifying basal cells in benign glands was 88.37% and 90.70% respectively.
  • Thus, p63 is a useful complementary basal cell specific stain to HMW-CK, and would be very helpful to practicing pathologists in dealing with difficult cases.
  • [MeSH-major] Keratins. Membrane Proteins. Neoplasms / diagnosis. Neoplasms, Basal Cell / diagnosis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Humans. Malaysia. Male. Molecular Weight. Prostatic Neoplasms / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682568.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


79. Svensson Månsson S, Reis-Filho J, Landberg G: Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co-localization with the gamma 2 chain of laminin-332. J Pathol; 2007 May;212(1):102-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co-localization with the gamma 2 chain of laminin-332.
  • Basal cell carcinoma cells show low proliferation rates at the invasive front and a concordant upregulation of the cdk-inhibitor p16, limiting proliferative capacity.
  • Little is known about the mechanisms of p16 regulation in normal and malignant cells apart from that many transcription factors such as Ets1, Ets2, SP1, SP3, JunB and the polycomb protein Bmi1 have the potential to induce or repress p16 expression.
  • Therefore, the aim of this study was to determine how p16 is regulated in basal cell carcinoma with special focus on its upregulation in invasive cells.
  • By analysing various microdissected areas of basal cell carcinoma using real-time quantitative PCR we observed upregulation of p16 mRNA in invasive tumour cells compared to centrally localized tumour cells.
  • The methylation status of the p16 promoter, analysed by methylation-specific PCR, also showed diminished methylation in tumour cells at the invasive front, supporting the hypothesis that promoter methylation can affect the transcriptional activation of p16 in vivo.
  • Interestingly, in basal cell carcinoma we observed partial co-localization between p16 and the gamma 2 chain of laminin-332 in tumour cells towards areas of ulceration and in the majority of clearly infiltrative tumour cells but not in p16 positive tumour cells with a more pushing invasive growth pattern.
  • These data suggest that concurrent p16 upregulation and decreased proliferation are more general phenomena in different types of invasive growth patterns in basal cell carcinomas and that these only partially overlap with the gamma 2 chain of laminin-332 associated invasion patterns.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / genetics. Gene Expression Regulation, Neoplastic. Genes, p16. Laminin / analysis. Promoter Regions, Genetic
  • [MeSH-minor] Blotting, Western. Cell Adhesion Molecules / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA Methylation. Humans. Immunohistochemistry. Neoplasm Invasiveness. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17370299.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Laminin; 0 / RNA, Messenger; 0 / kalinin
  •  go-up   go-down


80. Karen JK, Gareau DS, Dusza SW, Tudisco M, Rajadhyaksha M, Nehal KS: Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy. Br J Dermatol; 2009 Jun;160(6):1242-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy.
  • Nuclear and cellular morphology is observed in thin optical sections, similar to that in conventional histology.
  • OBJECTIVES: To evaluate the sensitivity and specificity of ex vivo real-time imaging with fluorescence confocal mosaicing microscopy, using acridine orange, for the detection of residual basal cell carcinoma (BCC) in Mohs fresh tissue excisions.
  • Very good correlation was observed between confocal mosaics and matched Mohs frozen sections for benign and malignant skin structures, overall tumour burden and location, and identification of all major histological subtypes of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):923-8 [15313861.001]
  • [Cites] J Cell Biol. 1985 Apr;100(4):1309-23 [3920227.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]
  • [Cites] J Biomed Opt. 2005 May-Jun;10(3):034009 [16229653.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]
  • [Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] Opt Lett. 2006 Sep 15;31(18):2756-8 [16936882.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014005 [17343480.001]
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1248-55 [17989735.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):152-61 [18460029.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044016 [19021344.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • (PMID = 19416248.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS95359; NLM/ PMC2693082
  •  go-up   go-down


81. Asif M, Mamoon N, Ali Z, Akhtar F: Epidemiological and excision margin status of Basal cell carcinoma--three years Armed Forces Institute of Pathology experience in Pakistan. Asian Pac J Cancer Prev; 2010;11(5):1421-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and excision margin status of Basal cell carcinoma--three years Armed Forces Institute of Pathology experience in Pakistan.
  • OBJECTIVE: The rationale of this study is to analyze the demographic distribution and clearance of excision margin in basal cell carcinoma among patients diagnosed at AFIP Rawalpindi.
  • MATERIALS AND METHODS: Records of a total of 235 cases diagnosed from January 2005 to December 2007 were retrieved from our tumour registry.
  • CONCLUSION: Basal cell carcinoma (BCC) appears to be on the rise in our part of world.
  • [MeSH-major] Carcinoma, Basal Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cheek / pathology. Eye Neoplasms / epidemiology. Eye Neoplasms / pathology. Female. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Humans. Male. Middle Aged. Nose Neoplasms / epidemiology. Nose Neoplasms / pathology. Pakistan / epidemiology. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198304.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


82. Mavrikakis I, Malhotra R, Selva D, Huilgol SC, Barlow R: Linear basal cell carcinoma: A distinct clinical entity. J Plast Reconstr Aesthet Surg; 2006;59(4):419-23
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear basal cell carcinoma: A distinct clinical entity.
  • The purpose of the study is to describe linear basal cell carcinoma (BCC) as a distinct clinical entity, and highlight its existence to the plastic surgery literature.
  • Presence of the tumour along relaxing skin tension lines, increase in subclinical extension, and aggressive tumour behavior are reported observations.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756260.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 18
  •  go-up   go-down


83. Mc Loone NM, Tolland J, Walsh M, Dolan OM: Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):698-701
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of basal cell carcinomas: an audit of current practice.
  • BACKGROUND: Follow-up of patients after treatment of basal cell carcinoma (BCC) allows for monitoring of recurrence and detection of new tumours, but adds a significant burden to outpatient clinics.
  • At the skin tumour clinic in the dermatology department, the Royal Hospitals, Belfast, all patients are reviewed for 2 years after surgical excision of a low-risk primary BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Guideline Adherence. Practice Guidelines as Topic. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Practice Patterns, Physicians' / statistics & numerical data. Prognosis. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836498.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett; 2008 May 8;263(1):89-98
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma.
  • Annexin A2 is a highly expressed gene with important roles in cell membrane physiology and is frequently dysregulated in cancer.
  • The objective of this study was to determine the pattern of expression and prognostic significance of annexin A2 protein in head and neck squamous cell carcinoma.
  • Annexin A2 expression was confined to the basal and suprabasal cells of normal epithelium and the protein cellular location was consistently observed at the cell membrane.
  • We conclude that annexin A2 exhibits a characteristic pattern of expression, distinct from other annexins and suggestive of a cell-specific functional role.
  • The phenotypic consequences may become manifest in an alteration of epithelial tissue growth and remodelling with secondary influence on tumour development, progression and metastasis.
  • [MeSH-major] Annexin A2 / metabolism. Carcinoma, Squamous Cell / metabolism. Down-Regulation. Head and Neck Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262347.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Annexin A2
  •  go-up   go-down


85. Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J: Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep; 2005 Jan;13(1):151-5
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population.
  • Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses, squamous cell carcinomas or basal cell carcinomas by specific enzyme-linked immunobiological assays.
  • The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses, squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583817.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
  •  go-up   go-down


86. Dissemond J, Grabbe S: [Non-surgical therapy of basal cell carcinoma of the head-neck region]. Laryngorhinootologie; 2006 Feb;85(2):133-41; quiz 142-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-surgical therapy of basal cell carcinoma of the head-neck region].
  • Basal cell carcinoma is a semi-malignant epithelial skin tumour with a locally destructive growth pattern but a very low tendency to metastases.
  • Basal cell carcinoma represent the most frequent malignant cutaneous tumour worldwide in white population with a lifetime risk of 30 % and still increasing incidence.
  • Basal cell carcinoma are predominantly located in the central region of the face.
  • The very rarely observed occurrence of metastases seems to be a result of insufficient therapy or a metatypic basal cell carcinoma type.
  • Therapy of first choice of basal cell carcinoma is the complete, micrographically controlled excision.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498544.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 144O8QL0L1 / Diclofenac; 8W8T17847W / Urea; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 15
  •  go-up   go-down


87. Szabo B, Szabo I, Mera M, Fripcea AM: [Keratotic basal cell carcinoma with orbital extension--case report]. Oftalmologia; 2005;49(2):43-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keratotic basal cell carcinoma with orbital extension--case report].
  • This is a description of a case of a 72-year-old female who developed a basal cell carcinoma of the external angle of the eyelid, with intraorbital extension.
  • The tumour of the eyelid and orbit was completely removed with good postoperative course and a good outcome without recurrence in the past 3 years.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Eyelid Neoplasms / etiology. Keratosis / complications. Orbital Neoplasms / etiology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Invasiveness. Treatment Outcome. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245743.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


88. Rafindadi AH, Samaila MO: Histopathologic analysis of epidermal skin tumours and tumour-like lesions in Ahmadu Bello University Teaching Hospital, Zaria. Niger Postgrad Med J; 2006 Dec;13(4):354-6
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic analysis of epidermal skin tumours and tumour-like lesions in Ahmadu Bello University Teaching Hospital, Zaria.
  • OBJECTIVE: A histopathologic analysis of epidermal skin tumours and tumour-like lesions seen between 1991 - 2000 in the Department of Pathology, Ahmadu Bello University Teaching Hospital [A.B.U.T.H], Zaria is presented.
  • RESULTS: A total of 350 such lesions comprising 9.9% of all cutaneous neoplasms seen within the study period were collected.
  • Malignant tumours constituted 72.5%; benign tumours 18.3% and tumour-like lesions 9.2%.
  • The commonest malignant lesion was squamous cell carcinoma, which constituted 68.3% of all the lesions with a male to female ratio of 1.7:1.
  • CONCLUSION: It is concluded that epidermal tumours and tumour-like lesions are not uncommon in Zaria and they show a male preponderance with squamous cell carcinoma being the commonest epidermal tumour and it also predominantly affects males.
  • [MeSH-major] Skin Diseases / epidemiology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Age Distribution. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Epidermal Cyst / epidemiology. Female. Hospitals, Teaching. Humans. Keratoacanthoma / epidemiology. Keratosis, Seborrheic / epidemiology. Male. Nigeria / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203131.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


89. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abundant expression of AMACR in many distinct tumour types.
  • AIMS: Alpha-methylacyl-CoA racemase (AMACR), a mitochondrial and peroxisomal enzyme, is a valuable tool to confirm the diagnosis of prostate cancer, especially if combined with basal cell markers.
  • To extend this diagnostic utility to other neoplasias, we comprehensively surveyed AMACR expression in human tumours.
  • METHODS: We performed immunohistochemical analyses on tissue microarrays of AMACR expression in over 125 different human tumour types and 80 normal tissues.
  • RESULTS: Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


90. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


91. Griffiths RW, Suvarna SK, Stone J: Basal cell carcinoma histological clearance margins: an analysis of 1539 conventionally excised tumours. Wider still and deeper? J Plast Reconstr Aesthet Surg; 2007;60(1):41-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma histological clearance margins: an analysis of 1539 conventionally excised tumours. Wider still and deeper?
  • An analysis of peripheral and deep margins of histological clearance around 1539 consecutive basal cell carcinomas excised by conventional surgery showed that 81 lesions (5.3%) were incompletely excised peripherally; 36 lesions (2.3%) were incompletely excised deeply; 13 lesions (0.8%) were incompletely excised peripherally and deeply.
  • This study of conventional surgical excision of basal cell carcinomas with an incomplete excision rate of 8% has shown that 65% of lesions were excised with <5mm histological clearance peripherally and 85% with <5mm deep clearance.
  • These figures for 'normal tissue sacrifice' are not excessive when compared with those of 'tissue sparing' Mohs' micrographic surgery in which the operator may take a margin of several millimetres of normal tissue in the initial 'slice', or in the subsequent 'safety margin' beyond the eventual tumour free plane.
  • However, peripheral margins did exceed 5mm in more than 30% of lesions of scalp, temple and forehead, and for these sites where even with loupe magnification the tumour edge could be difficult to define, either frozen section control or Mohs' technique, might with benefit be more often used in order to minimise normal tissue sacrifice.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126265.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Lewandowska U, Zelazowski M, Seta K, Byczewska M, Pluciennik E, Bednarek AK: WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol; 2009 May;60 Suppl 1:47-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WWOX, the tumour suppressor gene affected in multiple cancers.
  • WWOX is a tumour suppressor gene affected in multiple cancers, especially in breast, prostate and ovary.
  • WWOX turned out to possess tumour suppressor features despite the fact that the most basic (classical) way of tumour suppressor gene inactivation involves both alleles (e.g. through deletions, point mutations and promoter methylation), which is very rare event in a case of WWOX, occurring only in few cell lines.
  • A large number of papers corroborate the phenomenon of correlation between the loss of WWOX expression and more aggressive/worse prognosis in many different types of tumours, for example breast cancer, nonsmall cell lung cancer, bladder cancer, gastric cancer or sporadic meningiomas.
  • Ectopically increased WWOX expression promotes migration through basal membrane, however suppresses anchorage independent growth and induces normal-like colony formation in matrigel.
  • [MeSH-major] Genes, Tumor Suppressor. Neoplasms / metabolism. Oxidoreductases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609013.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human
  • [Number-of-references] 57
  •  go-up   go-down


93. Hamada S, Kersey T, Thaller VT: Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome. Br J Ophthalmol; 2005 Aug;89(8):992-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome.
  • AIM: To analyse the outcome of basal cell carcinoma (BCC) excision in a subregional (non-Mohs) oculoplastic service.
  • Tumour recurrence rate was derived from the 69 patients with a minimum 5 year follow up.
  • Of those reported incompletely excised 53% contained no tumour at re-excision.
  • [MeSH-major] Blepharoplasty / methods. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1967 Jun;39(6):619-24 [6026420.001]
  • [Cites] N Engl J Med. 1965 Oct 21;273(17):923-4 [5832875.001]
  • [Cites] J Surg Oncol. 1984 Feb;25(2):79-80 [6694405.001]
  • [Cites] J Surg Oncol. 1985 Jan;28(1):72-4 [3968892.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):186-96 [3950119.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] Ophthalmic Surg. 1993 Nov;24(11):755-8 [8290215.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] Plast Reconstr Surg. 1982 Jan;69(1):110-6 [7053498.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] AORN J. 2000 Mar;71(3):552-4, 556-8, 560-4; quiz 565-70 [10736640.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):430-6 [10990046.001]
  • [Cites] Br J Ophthalmol. 2001 Dec;85(12):1450-4 [11734520.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):257-63 [14871219.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):624-30 [15051192.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):926; author reply 926-7 [16782962.001]
  • [CommentIn] Br J Ophthalmol. 2006 May;90(5):660-1 [16622110.001]
  • (PMID = 16024851.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772767
  •  go-up   go-down


94. Baliga SD, Rao SS: Nevoid-basal cell carcinoma syndrome: a case report and overview on diagnosis and management. J Maxillofac Oral Surg; 2010 Mar;9(1):82-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid-basal cell carcinoma syndrome: a case report and overview on diagnosis and management.
  • Nevoid Basal Cell Carcinoma Syndrome (NBCCS) is a rare condition characterized by varied clinical manifestations like multiple Basal Cell Carcinomas (BCC), multiple Keratocystic Odontogenic Tumours (KCOT), palmar and/or plantar pits and ectopic calcification of the falx cerebri, which are considered as the major criteria for diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Plast Surg. 1977 Jan;30(1):62-7 [836983.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Sep;72(3):265-9 [1717918.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1991 Apr;99(4):294-7 [2008888.001]
  • [Cites] Ophthalmologica. 1990;200(2):104-6 [2160065.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Oral Surg. 1966 Jan;24(1):15-26 [5214558.001]
  • [Cites] J Maxillofac Surg. 1981 Nov;9(4):228-36 [6172530.001]
  • [Cites] Int J Oral Surg. 1980 Jun;9(3):173-9 [6777316.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 2):937-9 [8621834.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Int J Oral Maxillofac Surg. 1999 Jun;28(3):216-23 [10355946.001]
  • [Cites] J Lab Clin Med. 1999 Dec;134(6):551-2 [10595780.001]
  • [Cites] Pediatr Dent. 2000 Jan-Feb;22(1):53-5 [10730288.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):553-8 [11077375.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Mar;33(2):117-24 [15050066.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] Int J Paediatr Dent. 2004 Jul;14(4):279-87 [15242385.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1662-6 [16243184.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Aug;102(2):217-9 [16876065.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Cancer. 1980 Sep 15;46(6):1456-62 [7417945.001]
  • (PMID = 23139577.001).
  • [ISSN] 0972-8279
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453702
  • [Keywords] NOTNLM ; Gorlin-Goltz syndrome / Keratocystic odontogenic tumour / Nevoid basal cell carcinoma syndrome
  •  go-up   go-down


95. de Haas ER, de Bruijn HS, Sterenborg HJ, Neumann HA, Robinson DJ: Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy. Acta Derm Venereol; 2008;88(6):547-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy.
  • Light fractionation in aminolaevulinic acid photodynamic therapy (PDT) of superficial basal cell carcinoma has been shown to enhance the therapeutic efficacy significantly.
  • The present study investigated the spatial distribution of protoporphyrin in 32 superficial basal cell carcinomas undergoing light-fractionated PDT.
  • The microscopic distribution of fluorescence was also compared with tumour sections immunohistochemically stained for Ki-67.
  • The general distribution of cells stained positive for Ki-67 followed the protoporphyrin fluorescence that was associated with islands of basal cell carcinoma.
  • There are large variations in fluorescence within superficial basal cell carcinoma that include regions of tumour cells that do not synthesize protoporphyrin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Photochemotherapy. Photosensitizing Agents / pharmacokinetics. Protoporphyrins / pharmacokinetics. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002337.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


96. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P: Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol; 2008 Nov;33(6):745-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans.
  • Histological examination confirmed complete tumour regression.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Beta Particles / therapeutic use. Face. Female. Follow-Up Studies. Humans. Male. Nose Neoplasms / radiotherapy. Ointments. Radiotherapy Dosage. Remission Induction. Rhenium / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681873.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ointments; 7440-15-5 / Rhenium
  •  go-up   go-down


97. Erba P, Wettstein R, Rieger UM, Beltraminelli H, Pierer G, Kalbermatten DF: Reducing the learning curve for the treatment of morphoeic (sclerosing) basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg; 2008;42(3):122-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing the learning curve for the treatment of morphoeic (sclerosing) basal cell carcinoma of the face.
  • The treatment of morphoeic (or sclerosing) basal cell carcinoma (mBCC) of the face is associated with high rates of incomplete excision and recurrence.
  • The extent of the tumour was assessed under standard conditions by consultant surgeons and compared with assessments by resident surgeons with the help of the Varioscope, a combination of microscope and loupe glasses with strong illumination and a maximal magnification of 7x.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470787.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


98. Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N: The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose. Med J Malaysia; 2008 Oct;63(4):339-40
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
  • Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.
  • The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385500.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


99. Stenquist B, Ericson MB, Strandeberg C, Mölne L, Rosén A, Larkö O, Wennberg AM: Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery. Br J Dermatol; 2006 Feb;154(2):305-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery.
  • BACKGROUND: Fluorescence imaging is an attractive diagnostic technique for skin tumour demarcation with potential to move to clinical use.
  • To evaluate the technique, fluorescence data must be compared with the histopathological extent of the tumour, which is the purpose of the current study.
  • OBJECTIVES: To investigate the agreement between bispectral fluorescence images and the histopathological tumour boundary of ill-defined basal cell carcinomas (BCCs).
  • After fluorescence imaging the tumours were removed using Mohs micrographic surgery (MMS) to obtain histopathological maps of the tumour boundaries.
  • CONCLUSIONS: In this preliminary study the fluorescence has been compared with the histopathological tumour boundaries.
  • The result implies that the technique can be applied as a useful tool for indicating tumour boundary of aggressive BCCs.
  • Further refinement is needed to be able to indicate the exact tumour border.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Mohs Surgery. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433801.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


100. Gusterson BA, Ross DT, Heath VJ, Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res; 2005;7(4):143-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer.
  • However, it is important in developing hypotheses about the pathogenesis of this tumour type to review the nomenclature that is being used to emphasize potential confusion between terminology that defines clinical subgroups and markers of cell lineage.
  • This article reviews the lineages in the normal breast in relation to what have become known as the 'basal-like' carcinomas.
  • [MeSH-major] Breast / cytology. Breast Neoplasms / classification. Breast Neoplasms / physiopathology. Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / physiopathology. Keratins / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Jan;193(1):27-32 [11169512.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):703-11 [15459022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Dis Markers. 2001;17(2):99-109 [11673656.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1525-33 [12429812.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:533-40 [12454650.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):1-8 [12610349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:33-44 [14521514.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:73-84 [14521517.001]
  • [Cites] Am J Clin Pathol. 1989 Apr;91(4 Suppl 1):S14-8 [2467554.001]
  • [Cites] J Cell Sci. 1989 Nov;94 ( Pt 3):403-13 [2483723.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):751-63 [1705754.001]
  • [Cites] Cell Growth Differ. 1990 Apr;1(4):161-70 [1707299.001]
  • [Cites] J Med Genet. 2004 Jan;41(1):1-5 [14729816.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Cancer Cell. 2004 May;5(5):489-500 [15144956.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2523-36 [15034139.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4218-26 [15205334.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):444-60 [15212947.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Breast Cancer Res. 2004;6(5):192-200 [15318924.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Science. 1976 Jan 23;191(4224):295-7 [1246614.001]
  • [Cites] Pathol Res Pract. 1980;166(4):515-35 [6253967.001]
  • [Cites] Cancer Res. 1982 Nov;42(11):4763-70 [6290045.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Exp Cell Res. 1985 Apr;157(2):520-32 [2579837.001]
  • [Cites] J Histochem Cytochem. 1986 Jul;34(7):869-81 [2423579.001]
  • [Cites] J Natl Cancer Inst. 1986 Aug;77(2):343-9 [2426509.001]
  • [Cites] Lancet. 1987 Feb 28;1(8531):514 [2881076.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):276-89 [2450059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94 [10535966.001]
  • [Cites] Histopathology. 2000 Aug;37(2):175-81 [10931242.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Differentiation. 1991 Apr;46(3):209-21 [1833254.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):800-6 [8760013.001]
  • [Cites] J Pathol. 1998 Feb;184(2):197-206 [9602712.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):119-29 [9737789.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Recent Results Cancer Res. 1998;152:35-48 [9928545.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):443-56 [15617686.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):422-7 [11487275.001]
  • (PMID = 15987465.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC1175069
  •  go-up   go-down






Advertisement